

Query Match 89.3%; Score 26.8; DB 6; Length 30;
 Best Local Similarity 93.3%; Pred. No. 0.39;
 Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 2
 AX032823 LOCUS AX032823 Sequence 1 from Patent WO0044409. 30 bp DNA linear PAT 21-SEP-2000
 ACCESSION AX032823 VERSION AX032823.1 GI:10279797
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM synthetic construct
 artificial sequences.

REFERENCE 1. Becker, D.L. and Green, C.R.
 AUTHORS Becker, D.L. and Green, C.R.
 TITLE Formulations comprising antisense nucleotides to connexins
 Patent: WO 0044409-A 1 03-AUG-2000;
 BECKER DAVID LAURENCE (GB) ; UNIV LONDON (GB) ; GREEN COLIN RICHARD (NZ)
 JOURNAL
 FEATURES Location/Qualifiers
 1..30
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Oligonucleotide"
 ORIGIN

Query Match 100.0%; Score 30; DB 6; Length 30;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTATTGGCCAGAAGATTGGTTCTGTC 30
 Db 1 GTATTGGCCAAAGATTGGTTCTGTC 30

RESULT 3
 BD237980 LOCUS BD237980 Formulations comprising antisense nucleotides to connexins. 30 bp DNA linear PAT 17-JUL-2003
 ACCESSION BD237980 VERSION BD237980.1 GI:33047750
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM synthetic construct
 artificial sequences.
 (bases 1 to 30)
 Becker, D.L. and Green, C.R.
 Formulations comprising antisense nucleotides to connexins
 Patent: JP 2002535377-A 2 22-OCT-2002;
 UNIVERSITY COLLEGE LONDON
 OS Artificial Sequence
 PN JP 2002535377-A/7
 PD 22-OCT-2002
 PF 27-JAN-2000 JP 2000595711
 PR 27-JAN-1999 NZ 333928,07-OCT-1999 NZ 500190 PI
 DAVID LAURENCE BECKER, COLIN RICHARD GREEN
 PC A61K31/711, A61K9/06, A61K9/10, A61K47/16, A61K47/34, A61K47/46, PC
 PC A61K48/00/
 PC A61P17/02, A61P17/12, A61P17/16, A61P25/00, A61P29/00, A61P43/00/
 PC A61P43/00//
 PC C12N15/09, C12N15/00
 CC Description of Artificial Sequence: Oligonucleotide FH
 KEY
 source 1..30
 /organism="Artificial Sequence".
 Location/Qualifiers

FEATURES Source
 1..30
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

ORIGIN

Query Match 89.3%; Score 26.8; DB 6; Length 30;
 Best Local Similarity 93.3%; Pred. No. 0.39;
 Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 5
 BD237989 LOCUS BD237989 Formulations comprising antisense nucleotides to connexins. 30 bp DNA linear PAT 17-JUL-2003
 ACCESSION BD237989 VERSION BD237989.1 GI:33047759
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM synthetic construct
 artificial sequences.
 (bases 1 to 30)
 Becker, D.L. and Green, C.R.
 Formulations comprising antisense nucleotides to connexins
 Patent: JP 2002535377-A/11
 UNIVERSITY COLLEGE LONDON
 OS Artificial Sequence
 PN JP 2002535377-A/11

FEATURES Source
 1..30
 /organism="Artificial Sequence".
 Location/Qualifiers
 1..30
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

ORIGIN

PD 22-OCT-2002
 PR 27-JAN-1999 JP 200005957119-1999
 PR 27-JAN-1999 NZ 333128,07-OCT-1999
 PC A61K31/711,A61K9/06,A61K9/10,A61K47/16,A61K47/34,A61K47/46, PC
 A61K48/00, A61P17/02,A61P17/12,A61P17/16,A61P25/00,A61P29/00,A61P43/00,
 PC A61P43/00/
 PC C12N15/09,C12N15/00
 PC Description of Artificial Sequence: Oligonucleotide FA
 CC Key
 FEATURES Location/Qualifiers
 FT source 1..30
 /organism='Artificial Sequence'.
 FT Location/Qualifiers
 1..30
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 ORIGIN
 Query Match 89.3%; Score 26.8; DB 6; Length 30;
 Best Local Similarity 93.3%; Pred. No. 0..39;
 Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 RESULT 8
 AX032833/c
 LOCUS AX032833
 DEFINITION Sequence 11 from Patent WO0044409.
 ACCESSION AX032833
 VERSION AX032833.1 GI:10279807
 KEYWORDS synthetic construct
 synthetic construct
 artificial sequences.
 REFERENCE Becker, D.L. and Green, C.R.
 AUTHORS Formulations comprising antisense nucleotides to connexins
 TITLE Patent: WO 0044409-A 11 03 AUG-2000;
 JOURNAL BECKER DAVID LAURENCE (GB); GREEN COLIN RICHARD
 (NZ)
 FEATURES Location/Qualifiers
 1..30
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Oligonucleotide"
 ORIGIN
 Query Match 89.3%; Score 26.8; DB 6; Length 30;
 Best Local Similarity 93.3%; Pred. No. 0..39;
 Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 RESULT 9
 BD237986
 LOCUS BD237986
 DEFINITION Formulations comprising antisense nucleotides to connexins
 ACCESSION BD237986
 VERSION BD237986.1 GI:33047756
 KEYWORDS synthetic construct
 synthetic construct
 artificial sequences.
 REFERENCE Becker, D.L. and Green, C.R.
 AUTHORS Formulations comprising antisense nucleotides to connexins
 TITLE Patent: JP 2002535377-A 8 22-OCT-2002;
 JOURNAL UNIVERSITY COLLEGE LONDON
 COMMENT OS Artificial Sequence
 PN JP 2002535377-A/8
 PD 22-OCT-2002
 FEATURES Location/Qualifiers
 FT source 1..30
 /organism='Artificial Sequence'.
 FT Location/Qualifiers
 1..30
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Oligonucleotide"
 ORIGIN
 Query Match 89.3%; Score 26.8; DB 6; Length 30;
 Best Local Similarity 93.3%; Pred. No. 0..39;
 Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 RESULT 10
 AX032829
 LOCUS AX032829
 DEFINITION Sequence 7 from Patent WO0044409.
 ACCESSION AX032829
 VERSION AX032829.1 GI:10279803
 KEYWORDS synthetic construct
 synthetic construct
 artificial sequences.
 REFERENCE 1

Patent US 6635475-A 17 21-OCT-2003; Location/Qualifiers 1..43 /organism="unknown" /mol_type="genomic DNA"

Query Match 56.7%; Score 17; DB 6; Length 43; Best Local Similarity 80.0%; Pred. No. 1e+04; Matches 20; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

ORIGIN Qy 2 TAATGCCCAAGAAGATTGTTTC 26 Db 31 TACGTGAGAAAGAAATGTTTC 7

Query Match 57.3%; Score 17.2; DB 6; Length 30; Best Local Similarity 73.3%; Pred. No. 8e+03; Matches 22; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

ACCESSION BX547960.1 GI:32440780 VERSION BX547960.1 GI:32440780 KEYWORDS STS; STS, sequence tagged site. SOURCE Arabidopsis thaliana (thale cress) ORGANISM Arabidopsis thaliana

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicots; core eudicots; Rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

Clarke,J.H., Bowles,B., Carter,J.J., Hart,D., McCullagh,B., Walsh,S., Langham,S., LeGrys,C., Jones,J.D.G. and Bevan,M.

Clarke,J.H., Direct Submission Unpublished (bases 1 to 65)

Clarke,J.H., Clarke,J.H., John Innes Centre, Colney Lane, Norwich, NR4 7UJ, UK

AT denotes an activation tag dissociation transposon within a single line; ET an enhancer trap dissociation transposon, GT a gene trap dissociation transposon, MT a mis-expression enhancer trap dissociation transposon, SM a defective suppressor mutator transposon. -3 denotes a sequence derived from the 3' end of the transposon. -5 denotes a sequence derived from the 5' end of the transposon. BBSRC Garnet, ATIS project On-line seed stock requests: <http://nasc.nott.ac.uk/> NASC stock code: N12555.

FEATURES SOURCE 1..65 /organism="Arabidopsis thaliana" /mol_type="genomic DNA" /variety="Columbia-0" /db_xref="Columbia-0" /clone="Caxon-3702" /note="Derived from superpool 17.29 NASC code N40772"

Query Match 56.0%; Score 16.8; DB 11; Length 65; Best Local Similarity 90.0%; Pred. No. 1.3e+04; Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

ORIGIN Qy 4 ATGGGGCAGAGAGATGT 23 Db 19 ATTGGTCAACAGGGGATTGTTCTCGTC 38

Query Match 57.3%; Score 17.2; DB 6; Length 30; Best Local Similarity 73.3%; Pred. No. 8e+03; Matches 22; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

ACCESSION AR411028 VERSION AR411028 KEYWORDS Unknown. SOURCE Unknown.

ORGANISM Unclassified. REFERENCE 1 (bases 1 to 43) AUTHORS Helmann,J.D.

RESULT 13 AX952037/c LOCUS Sequence 17 from patent US 6635475. DEFINITION Sequence 94 from Patent WO03093504.

ACCESSION	AX952037	GI:	40782419	TITLE	Method for amplifying nucleic acids
KEYWORDS	synthetic construct			JOURNAL	WO 03093404-A 68 13-NOV-2003;
SOURCE	synthetic construct			FEATURES	Noxxon Pharma AG (DE)
ORGANISM	artificial sequences.			source	Location/Qualifiers
REFERENCE	1. Vater,A., Jarosch,F., Wattich,A. and Klussmann,S.				1. 49
AUTHORS	Patent: WO 03093504-A 94 13-NOV-2003;				/organism="synthetic construct"
JOURNAL	Noxxon Pharma AG (DE)				/mol type="unassigned RNA"
FEATURES	Location/Qualifiers				/db_Xref="taxon:32630"
source	1. 50				
ORGANISM	/organism="synthetic construct"				
	/mol type="unassigned RNA"				
	/db_Xref="taxon:32630"				
RESULT 14	Query Match	55.3%	Score 16.6; DB 6; Length 50;	Query Match	54.0%; Score 16.2; DB 6; Length 49;
	Best Local Similarity	82.6%	Pred. No. 1.5e+04; Indels 0; Gaps 0;		Best Local Similarity 72.4%; Pred. No. 2.3e+04; Indels 0; Gaps 0;
	Matches 19; Conservative	0;	Mismatches 4;		Matches 21; Conservative 0; Mismatches 8;
Qy	8 CGGGCAAGAAGAATGTTCTGTC 30			Qy	2 TAATTCGGGCAAGAGAAATGTTCTGTC 30
Db	36 CGTCAGACGAAATCGTTCTTC 14			Db	42 TCATCGTCACAGAGAAATGTTCTTC 14
SEARCH COMPLETED	November 5, 2004, 16:35:12				
JOBTIME	2550 secs				

ACCESSION	AX922631/C	AX952631	50 bp RNA	linear	PAT 08-JAN-2004
KEYWORDS	Sequence 186 from Patent WO03093472.				
SOURCE	AX952631				
ORGANISM	artificial sequences.				
REFERENCE	1. Vater,A., Maasch,C., Jarosch,F., Bell,M., Helmling,S., Klussmann,S., Ruppert,T., Schien,K., Bahrnert,B., Mozyroud,E., Stark,S., and Gillen,C.				
AUTHORS	Cgrp binding nucleic acids				
JOURNAL	Patent: WO 03093472-A 186 13-NOV-2003;				
FEATURES	Gruenenthal GmbH (DE) ; Noxxon Pharma AG (DE)				
source	1. 50				
ORGANISM	/organism="synthetic construct"				
	/mol type="unassigned RNA"				
	/db_Xref="taxon:32630"				
	/note="CGRP-binding nucleic acid"				
RESULT 15	Query Match	55.3%	Score 16.6; DB 6; Length 50;	Query Match	55.3%; Score 16.6; DB 6; Length 50;
	Best Local Similarity	82.6%	Pred. No. 1.5e+04; Indels 0; Gaps 0;		
	Matches 19; Conservative	0;	Mismatches 4;		
Qy	8 CGGCAGAGAAGAATGTTCTGTC 30				
Db	36 CGTCAGACGAAATCGTTCTTC 14				
SEARCH COMPLETED	November 5, 2004, 16:35:12				
JOBTIME	2550 secs				



GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

CM nucleic - nucleic search, using sw model
Run on: November 5, 2004, 13:14:14 ; Search time 343 Seconds
(without alignments)
459.133 Million cell updates/sec

Title: US-09-890-363-1
Perfect score: 30
Sequence: 1 gtaattgcggcaagaatgtttctgtc 30

Scoring table: IDNTNTY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 4134886 seqs, 2624710521 residues

Total number of hits satisfying chosen parameters: 4224225

Minimum DB seq length: 0
Maximum DB seq length: 75

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_23Sep04:*

- 1: Geneseqn1980s:*
- 2: Geneseqn190s:*
- 3: Geneseqn2000s:*
- 4: Geneseqn2001as:*
- 5: Geneseqn2001bs:*
- 6: Geneseqn2002as:*
- 7: Geneseqn2002bs:*
- 8: Geneseqn2003as:*
- 9: Geneseqn2003bs:*
- 10: Geneseqn2003cs:*
- 11: Geneseqn2003ds:*
- 12: Geneseqn2004s:*

- Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB ID	Description	
1	30	100.0	30	3	AAA71646	Aaa71646 Connexin	
2	26.8	89.3	30	3	AAA71647	Aaa71647 Connexin	
c	3	26.8	89.3	30	3	Aaa71652	Aaa71652 Connexin
4	17.2	57.3	30	3	AAA71653	Aaa71653 Chicken C	
c	5	17	56.7	43	10	ADP50888	Adi50888 Bacillus
c	6	16.6	55.3	50	11	ADM73609	ADM73609 CGRP-bind
c	7	16.6	55.3	50	11	ADM68129	ADM68129 Oligonucl
c	8	16.6	55.3	50	11	ADM68130	ADM68130 Oligonucl
c	9	16.2	54.0	49	11	ADM73616	ADM73616 CGRP-bind
c	10	16.2	54.0	49	11	ADM73583	ADM73583 CGRP-bind
c	11	16.2	54.0	49	11	ADM67585	ADM67585 Rat alpha
c	12	16.2	54.0	49	11	ADM68137	ADM68137 Oligonucl
c	13	16.2	54.0	49	11	ADM68140	ADM68140 Rat alpha
c	14	16.2	54.0	49	11	ADM67811	ADM67811 Rat alpha
c	15	16.2	54.0	49	11	ADM67825	ADM67825 Rat alpha
c	16	16.2	54.0	60	6	ABN35256	ABN35256 Human spl
c	17	16.2	54.0	70	2	AAV23259	AAV23259 Synthetic
c	18	15.8	52.7	47	3	AAB78224	AAB78224 Pinacada
c	19	15.8	52.7	41	6	AAV50652	AAV50652 Brassica
c	20	15.8	52.7	41	6	ABL18067	ABL18067 Brassica
c	21	15.6	52.0	24	6	ABL41518	ABL41518 Primer GT

ALIGNMENTS

RESULT 1
AAA71646
ID AAA71646 standard; DNA; 30 BP.
XX AAA71646;
AC
XX 15-DEC-2000 (first entry)
XX DB Connexin 43 primer DNA #1.
XX Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;
vulnerary; antiinflammatory; dermatology; site-specific downregulation;
neuronal insult; brain; spinal cord; optic nerve; wound healing;
inflammation reduction; scar formation; epithelial basal cell division;
keratinization; skin rejuvenation; primer; ss.
XX Unidentified.
OS
XX WO200044409-A1.
XX PD 03-AUG-2000.
XX PP 27-JAN-2000; 2000WO-GB000238.
XX PR 27-JAN-1999; 99NZ-00333928.
PR 07-OCT-1999; 99NZ-00500190.
XX PA (UNIL) UNIV COLLEGE LONDON.
PI Becker DL, Green CR;
XX DR WPI; 2000-491220/43.
PS Claim 9; Page 2; 64pp; English.

This invention describes a novel formulation (I) for use in therapeutic and/or cosmetic treatment, comprising at least one antisense polynucleotide (II) to a connexin protein together with a carrier or vehicle. The products of the invention have neuroprotective, vulnerary, antiinflammatory and dermatological activity. (II) is useful in a

CC resulting from neuronal insult to a specific site in the brain, spinal
 CC cord or optic nerve of a patient, for promoting wound healing, resulting
 CC from trauma, burns or surgery and for reducing inflammation as a result
 CC of a wound or physical trauma of the brain, spinal cord or optic nerve
 CC and for decreasing scar formation. (I) containing (II) directed to
 CC connexin 43 or 31.1 is administered to regulate epithelial basal cell
 CC division and growth or to regulate outer layer keratinization,
 CC respectively, for skin rejuvenation or thickening for cosmetic or
 CC therapeutic purposes (I) downregulates connexin expression in a highly
 CC desirable site-specific manner. This sequence represents a connexin-43
 CC directed oligonucleotide which is used in the method of the invention

XX Sequence 30 BP; 6 A; 4 C; 10 G; 10 T; 0 U; 0 Other;

XX Query Match 89.3%; Score 26.8; DB 3; Length 30;
 XX Best Local Similarity 93.3%; Prd. No. 0.054;
 XX Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0

Qy 1 GTTATTGGCCAGGAAAGATTGTTCTCTC 30
 Db 1 GTTATTGGCCAGGAGGATTGTTCTCTC 30

RESULT 3
 AAA71652/c
 ID AAA71652 standard; DNA; 30 BP.
 XX
 AC AAA71652;
 XX
 DT 15-DEC-2000 (first entry)
 XX Connexin 43 primer DBIsense DNA.
 XX
 KW Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;
 KW vulnerability; antiinflammation; dermatology; site-specific downregulation;
 KW neuronal insult; brain; spinal cord; optic nerve; wound healing;
 KW inflammation reduction; scar formation; epithelial basal cell division;
 KW keratinization; skin rejuvenation; primer; ss.
 XX Unidentified.
 OS
 PN WO200044409-A1.
 XX
 PD 03-AUG-2000.
 XX
 PF 27-JAN-2000; 2000WO-GB000238.
 XX
 PR 27-JAN-1999; 99NZ-00333928.
 PR 07-OCT-1999; 99NZ-00500190.
 XX
 PA (UNILO) UNIV COLLEGE LONDON.
 XX
 PI Becker DL, Green CR;
 XX
 DR WPI; 2000-491220/43.
 XX
 PT New formulation for therapeutic and/or cosmetic treatment of neuronal
 PT cell death, inflammation and scar formation, comprises antisense
 PT polynucleotide to connexin protein.
 XX
 Example 1; Page 17; 6APP; English.
 PS
 XX This invention describes a novel formulation (I) for use in therapeutic
 CC and/or cosmetic treatment, comprising at least one antisense
 CC polynucleotide (II) to a connexin protein together with a carrier or
 CC vehicle. The products of the invention have neuroprotective, vulnerability,
 CC antiinflammatory and dermatological activity. (II) is useful in a
 CC formulation (I), which is administered to a site on or within a patient
 CC for the site-specific downregulation of connexin protein expression. (I)
 CC is therefore specifically useful for reducing neuronal cell death
 CC resulting from neuronal insult to a specific site in the brain, spinal
 CC cord or optic nerve of a patient, for promoting wound healing resulting
 CC from trauma, burns or surgery and for reducing inflammation as a result

CC of a wound or physical trauma of the brain, spinal cord or optic nerve
 CC and for decreasing scar formation. (I) containing (II) directed to
 CC connexin 43 or 31.1 is administered to regulate epithelial basal cell
 CC division and growth or to regulate outer layer keratinization,
 CC respectively for skin rejuvenation or thickening for cosmetic or
 CC therapeutic purposes (I) downregulates connexin expression in a highly
 CC desirable site-specific manner. This sequence represents a connexin-43
 CC directed oligonucleotide which is used in the method of the invention
 XX

Sequence 30 BP; 10 A; 10 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 89.3%; Score 26.8; DB 3; Length 30;

Best Local Similarity 93.3%; Pred. No. 0.054; Pairs: 0; Gaps: 0;
 Matches 28; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GATATTGGCCAGAGATTTCTGTC 30

Db 30 GATATTGGCCAGAGATTTCTGTC 1

RESULT 4

AAA71653 standard; DNA; 30 BP.

XX

AC AAA71653;

XX

15-DEC-2000 (first entry)

XX

Chicken connexin 43 primer DB1 DNA.

DE

Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;

CC vulnerable; antiinflammatory; dermatology; site-specific downregulation;

CC neuronal insult; brain; spinal cord; optic nerve; wound healing;

CC inflammation reduction; scar formation; epithelial basal cell division;

CC keratinization; skin rejuvenation; primer; chicken; ss.

XX

OS Gallus sp.

XX

PN WO20004409-A1.

XX

PD 03-AUG-2000.

XX

PP 27-JAN-2000; 2000WO-GB000238.

XX

PR 27-JAN-1999; 99NZ-00333928.

XX

PR 07-OCT-1999; 99NZ-00500190.

XX

PA (UNIL) UNIV COLLEGE LONDON.

XX

PI Becker DL, Green CR;

XX

DR WPI; 2000-491220/43.

XX

PT New formulation for therapeutic and/or cosmetic treatment of neuronal

PT cell death, inflammation and scar formation, comprises antisense

PT polynucleotide to connexin protein.

XX

PS Example 1; Page 17; 64PP; English.

XX

CC This invention describes a novel formulation (I) for use in therapeutic
 CC and/or cosmetic treatment, comprising at least one antisense
 CC polynucleotide (II) to a connexin protein together with a carrier or
 CC vehicle. The products of the invention have neuroprotective, vulnerable,
 CC antiinflammatory and dermatological activity. (II) is useful in a
 CC formulation (I), which is administered to a site on or within a patient
 CC for the site-specific downregulation of connexin protein expression. (I)
 CC is therefore specifically useful for reducing neuronal cell death
 CC resulting from neuronal insult to a specific site in the brain, spinal
 CC cord or optic nerve of a patient, for promoting wound healing resulting
 CC from trauma, burns or surgery and for reducing inflammation as
 CC result of a wound or physical trauma of the brain, spinal cord or optic nerve
 CC and for decreasing scar formation. (I) containing (II) directed to
 CC connexin 43 or 31.1 is administered to regulate epithelial basal cell

CC division and growth or to regulate outer layer keratinization,
 CC respectively, for skin rejuvenation or thickening for cosmetic or
 CC therapeutic purposes (I) downregulates connexin expression in a highly
 CC desirable site-specific manner. This sequence represents a connexin-43
 CC directed oligonucleotide which is used in the method of the invention
 XX

Sequence 30 BP; 7 A; 5 C; 9 G; 9 T; 0 U; 0 Other;

Query Match 57.3%; Score 17.2; DB 3; Length 30;

Best Local Similarity 73.3%; Prod. No. 9.1e+02; Mismatches 8; Indels 0; Gaps 0;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTATTCGCGCAGAGAGATGGTTCTGTC 30

Db 1 GTATTCGACAGAGGGATTTCTGTC 30

RESULT 5

ADFS0888/C standard; DNA; 43 BP.

ID ADF50888; ID ADF50888;

XX AC ADF50888;

XX DT 12-FEB-2004 (first entry)

XX Bacillus subtilis yfhL DNA oligo homologous to sigW.

XX DE

XX ss; ECF; sigma factor; extracytoplasmic function;
 XX autoregulatory promoter; Px; sigW; Pw; detoxification; antimicrobial;
 XX bacterial growth; replication; sigW.

XX Bacillus subtilis.

XX OS US6615475-B1.

XX PN Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX WPI; 2003-810568/76.

XX DR New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX PT alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX (CORR) CORNELL RES FOUND INC.

XX PA (CORR) CORNELL RES FOUND INC.

XX PD 21-OCT-2003.

XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

QY 2 TAATGGCCAAGGAGATTGTTTC 26
 Db 31 TACGTGAAAGAGATGGTTTC 7

RESULT 6
 ADM73609/C ID ADM73609 standard, RNA; 50 BP.
 XX AC ADM73609;
 XX DT 03-JUN-2004 (first entry)

DE CGRP-binding ribo-oligonucleotide STAR-R02-15d-G12.
 XX
 KW antagonist; CGRP; calcitonin gene-related peptide; amylin; amyloid; splenomegaly; migraine; cluster headache; appetite loss; nausea; vomiting; neurogenic inflammation; vasodilation; hypotension; hypertension; KW tachycardia; trigeminal afferent sensory neuron activation; central nociceptive neuron; inflammatory pain; diabetes; KW gastric emptying; diabetic gastroparesis; polydipsia; ss.
 XX OS Synthetic.
 XX WO2003093472-A2.
 XX PR 13-NOV-2003.
 XX PF 06-MAY-2003; 2003WO-EPO004746.
 XX PR 06-MAY-2002; 2002DE-01020188.
 XX PR 04-NOV-2002; 2002DE-01051246.
 XX PA (CHEF) GRIESENTHAL GMBH.
 PA (NOXX-) NOXXON PHARMA AG.
 XX Vater A, Maasch C, Jarosch F, Bell M, Helmeling S, Eschgfäeller B;
 PI Moyroud E, Stark S, Klussmann S, Ruppert T, Schiene K, Bahrenberg G;
 PI Gillen C;
 XX WPI; 2003-854484/79.

PT New antagonists of calcitonin gene-related peptide or amylin, useful for
 PT treating or preventing e.g. migraine or inflammation, are specific
 PT binding nucleic acids.
 XX
 Claim 15; SEQ ID NO 186; 263pp; German.

CC This invention describes a novel antagonist of CGRP (calcitonin gene-related peptide), amylin or an amyloid polypeptide. A library of RNA (2'-fluoro substituted, on pyrimidine nucleotides) was incubated with biotinylated CGRP, for 3 hours at 37degC, then the incubation mixture applied to a matrix coated with streptavidin for 10 minutes at 37degC. The matrix was separated, washed with selection buffer and bound RNA recovered by elution with an excess of non-biotinylated CGRP. The bound RNA released this way was amplified and the selection procedure repeated for a total of 18 rounds, after which reverse transcription produced 192 clones. One sequence was present in 168 of these clones. This sequence had a Kd of 10 nM and was used as starting sequence for preparation of optimised and truncated RNA aptamers or spiegelmers (RTM). Antagonists of CGRP, amylin and amyloid polypeptides are useful for treating and/or preventing migraine, cluster headache, lack of appetite, nausea, or vomiting, neurogenic inflammation (especially where mediated by other neuropeptides), vasodilation, hypo- or hyper-tension, tachycardia, diseases that are associated with activation of trigeminal afferent sensory neurons and central nociceptive neurons (especially of the higher pain centres and including chronic inflammatory pain) and/or pain generally (chronic, acute, inflammatory, viseral or neuropathic), where CGRP is the target, and hypertension, diabetes, disorders of gastric emptying, diabetic gastroparesis and polydipsia, where amylin or amyloid peptides are the target. Antagonists that are nucleic acids are also useful for detecting CGRP, amylin and amyloid polypeptides or plagues, to screen for other CGRP and amylin antagonists or agonists, as starting

CC materials for rational drug design, for target validation and for studying CGRP or amylin function.

CC XX Sequence 50 BP; 16 A; 9 C; 16 G; 0 T; 9 U; 0 Other;

CC SQ Query Match 55.3%; Score 16.6; DB 11; Length 50;
 CC Best Local Similarity 82.6%; Prd. No. 1.8e+03; Indels 0; Gaps 0;

CC Matches 19; Conservative 0; Mismatches 4;

Qy 8 CGGGAAAGAGAAATGTTCTGTC 30
 Db 36 CGTCAGAGAACGTTCTTC 14

RESULT 7
 ADM68129/C ID ADM68129 standard; DNA; 50 BP.
 XX AC ADM68129;
 XX DT 03-JUN-2004 (first entry)

DE Oligonucleotide STAR-R02-15d-G12.
 XX nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.
 XX Synthetic.
 XX WO2003093504-A1.
 XX PR 13-NOV-2003.
 XX PF 06-MAY-2003; 2003WO-EPO04747.
 XX PR 06-MAY-2002; 2002DE-01020191.
 XX PA (NOXX-) NOXXON PHARMA AG.
 XX Vater A, Jarosch F, Wettich A, Klussmann S;

PT Amplification of nucleic acid using two adaptors, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.

XX Example 12; Fig 35; 262pp; German.

CC This invention describes a novel method for amplifying nucleic acids. The method comprises 1) preparing a target to be amplified, preferably RNA, having defined 5' and 3' sequences, separated by an intermediate sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic acid (especially one strand of RNA and the other DNA), where the 5'-end of the DNA strand has an overhang at least partly complementary with the 5'-end of the target, 3) preparing a second adapter (Ad2) of double stranded nucleic acid, where the first strand has a 5'-end that is at least partly complementary with the 3'-end of the target, the second strand also has a cleavage site which can generate a cleavage product that includes the complementary 3'-end of the second strand, 4) the adapters are ligated on the target, 5) reverse transcription is performed and optionally the second strand is synthesised. The products of the invention have antimigraine and analgesic activity. The method is especially used for selection and preparation of nucleic acids including L-nucleic acids, that bind to selected targets (aptamers), potentially useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin gene-related peptide) or amylin or their receptors, suitable for treatment of pain, migraine and other conditions, also as starting points for rational drug design, in screening for therapeutic compounds and for target validation. The method can be done in a single vessel, without purification of process intermediates and it can be applied to short

CC sequences.
 XX Sequence 50 BP; 16 A; 9 C; 16 G; 9 T; 0 U; 0 Other;
 SQ Query Match Similarity 55.3%; Score 16.6; DB 11; Length 50;
 Best Local Similarity 82.6%; Pred. No. 1.8e+03;
 Matches 19; Conservative 0; Mismatches 0;
 Indels 0; Gaps 0;
 Qy 8 CGGCAAGGAAATTGTTCTGTC 30
 Db 36 CGTCAGACGAAATCGTTCTTC 14

RESULT 8
 ADM67851/C
 ID ADM67851 standard; RNA; 50 BP.
 XX
 AC ADM67851;
 XX DT 03-JUN-2004 (first entry)
 DE Rat alpha-D-CGRP binding oligonucleotide SEQ ID 94.
 XX nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.
 XX Rattus sp.
 OS WO2003093504-A1.
 XX PD 13-NOV-2003.
 XX PF 06-MAY-2003; 2003WO-EP004747.
 XX PR 06-MAY-2002; 2002DE-01020191.
 XX PA (NOXX-) NOXXON PHARMA AG.
 XX PI Vater A, Jarosch F, Wettich A, Klussmann S;
 XX DR WO2003-854487/79.
 XX PT Amplification of nucleic acid using two adaptors, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.
 XX PS Example 12; SEQ ID NO 94; 262PP; German.
 XX
 UC This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
 acid (especially one strand of RNA and the other DNA), where the 5'-end
 CC of the DNA strand has an overhang at least partly complementary with the
 5'-end of the target, 3) preparing a second adapter (Ad2) of double
 CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
 on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
 CC least partly complementary with the 3'-end of the target, the second
 CC strand also has a cleavage site which can generate a cleavage product
 CC that includes the complementary 3'-end of the second strand, 4) the
 CC adaptors are ligated on the target, 5) reverse transcription is performed
 CC and optionally the second strand is synthesised. The products of the
 CC invention have antimigraine and analgesic activity. The method is
 CC especially used for selection and preparation of nucleic acids including
 CC L-nucleic acids that bind to selected targets (aptamers). Potentially
 CC useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin
 CC gene-related peptide) or amylin or their receptors, suitable for
 CC treatment of pain, migraine and other conditions, also as starting points
 CC for rational drug design, in screening for therapeutic compounds and for
 CC target validation. The method can be done in a single vessel, without
 CC purification of process intermediates and it can be applied to short
 CC sequences. ADM6759-ADM67903 represent Oligoribonucleotides capable of
 CC binding to rat CGRP which are used to illustrate the method of the
 CC invention.

CC Sequence 50 BP; 16 A; 9 C; 16 G; 0 T; 9 U; 0 Other;
 XX Query Match Similarity 55.3%; Score 16.6; DB 11; Length 50;
 Best Local Similarity 82.6%; Pred. No. 1.8e+03;
 Matches 19; Conservative 0; Mismatches 4;
 Indels 0; Gaps 0;
 Qy 8 CGGCAAGGAAATTGTTCTGTC 30
 Db 36 CGTCAGACGAAATCGTTCTTC 14

RESULT 9
 ADM73616/C
 ID ADM73616 standard; RNA; 49 BP.
 XX
 AC ADM73616;
 XX DT 03-JUN-2004 (first entry)
 DE CGRP-binding ribo-oligonucleotide STAR-R02-15xx-B10.
 XX antagonist; CGRP; calcitonin gene-related peptide; amylin; amyloid;
 KW spiegelmer; migraine; cluster headache; appetite loss; nausea; vomiting;
 KW neurogenic inflammation; vasodilation; hypertension; hypertension;
 KW tachycardia; trigeminal afferent sensory neuron; activation;
 KW central nociceptive neuron; inflammatory pain; diabetes;
 KW gastric emptying; diabetic gastroparesis; polydyspasia; ss.
 XX Synthetic.
 XX OS WO2003093472-A2.
 XX PN WO2003093472-A2.
 XX PD 13-NOV-2003.
 XX PR 06-MAY-2003; 2003WO-EP004746.
 XX PF 06-MAY-2002; 2002DE-01020188.
 XX PR 04-MAY-2002; 2002DE-01051246.
 XX PR 04-NOV-2002; 2002DE-01051246.
 XX (CHBF) GRIENENTHAL GMBH.
 XX PA (NOXX-) NOXXON PHARMA AG.
 XX PI Vater A, Maasch C, Jarosch F, Bell M, Helmeling S, Eschgfeller B;
 PI Moiraud E, Stark S, Klussmann S, Ruppert T, Schiene K, Bahnenberg G;
 PI Gillen C;
 XX DR WO2003-854484/79.
 XX PT New antagonists of calcitonin gene-related peptide or amylin, useful for
 PT treating or preventing e.g. migraine or inflammation, are specific
 PT binding nucleic acids.
 XX PS Claim 15; SEQ ID NO 193; 263PP; German.
 XX DR WO2003-854484/79.
 XX PT New antagonists of calcitonin gene-related peptide or amylin, useful for
 PT treating or preventing e.g. migraine or inflammation, are specific
 PT binding nucleic acids.
 XX PS This invention describes a novel antagonist of CGRP (calcitonin gene-
 CC related peptide), amylin or an amyloid polypeptide. A library of RNA (2'-
 CC fluoro substituted on pyrimidine nucleotides) was incubated with
 CC biotinylated CGRP, for 3 hours at 37degC, then the incubation mixture
 CC applied to a matrix coated with streptavidin for 10 minutes at 37degC.
 CC The matrix was separated, washed with selection buffer and bound RNA
 CC recovered by elution with an excess of non-biotinylated CGRP. The bound
 CC RNA released this way was amplified and the selection procedure repeated
 CC for a total of 18 rounds, after which reverse transcription produced 192
 CC clones. One sequence was present in 168 of these clones. This sequence
 CC had a Kd of 10 nM and was used as starting sequence for preparation of
 CC optimised and truncated RNA aptamers or spiegelmers (RPM). Antagonists of
 CC CGRP, amylin and amyloid polypeptides are useful for treating and/or
 CC preventing: migraine, cluster headache, lack of appetite, nausea,
 CC vomiting, neurogenic inflammation (especially where mediated by other
 CC neuropeptides), vasodilation, hypo- or hyper-tension, tachycardia,

diseases that are associated with activation of trigeminal afferent sensory neurons and central nociceptive neurons (especially of the higher pain centres and including chronic inflammatory pain) and/or pain generally (chronic, acute, inflammatory, visceral or neuropathic), where CGRP is the target and hypertension, diabetes, disorders of gastric emptying, diabetic gastroparesis and polydysia, where amylin or amyloid peptides are the target. Antagonists that are nucleic acids are also useful for detecting CGRP, amylin and amyloid polypeptides or plaques, to screen for other CGRP and amylin antagonists or agonists, as starting materials for rational drug design, for target validation and for studying CGRP or amylin function.

Sequence 49 BP; 16 A; 9 C; 16 G; 0 T; 8 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
Best Local Similarity 72.4%; Prd. No. 2.7e+03;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
Qy 2 TAATTCGCCAGAGAGATGTTCTGTC 30
Db 42 TCATCGTCCTAGAGATGTTCTTC 14

RESULT 10
ADM73583 standard; RNA; 49 BP.
ID ADM73583;
XX 03-JUN-2004 (first entry)
XX DE CGRP-binding ribo-oligonucleotide STAR-R02-12NM-E3.
XX antagonist; CGRP: calcitonin gene-related peptide; amylin; amyloid; spiegelmer; migraine; cluster headache; appetite loss; nausea; vomiting; neurogenic inflammation; vasodilation; hypotension; hypertension; tachycardia; trigeminal afferent sensory neuron activation; central nociceptive neuron; inflammatory pain; diabète; gastric emptying; diabetic gastroparesis; polydyspsia; ss;
XX Synthetic.
PN WO200303472-A2.
XX 13-NOV-2003.
XX DE 06-MAY-2003; 2003WO-EP004746.
XX PR 04-NOV-2002; 2002DE-01020188.
XX (CHEF) GRIESENTHAL GMBH.
PA (NOXX-) NOXXON PHARMA AG.

Vater A, Maasch C, Jarosch F, Bell M, Helmung S, Eschgfäller B, Bahnenberg G, Moyroud E, Stark S, Klussmann S, Ruppert T, Schiene K, Bahnenberg G, Gillen C;
DR 2003-854484/79.
XX New antagonists of calcitonin gene-related peptide or amylin, useful for PT treating or preventing e.g. migraine or inflammation, are specific PT binding nucleic acids.
XX Claim 15; SEQ ID NO 160; 263pp; German.

This invention describes a novel antagonist of CGRP (calcitonin gene-related peptide), amylin or an amyloid polypeptide. A library of RNA (2'-fluoro substituted on pyrimidine nucleotides) was incubated with biotinylated CGRP, for 3 hours at 37degC, then the incubation mixture applied to a matrix coated with streptavidin for 10 minutes at 37degC. The matrix was separated, washed with selection buffer and bound RNA recovered by elution with an excess of non-biotinylated CGRP. The bound

CC RNA released this way was amplified and the selection procedure repeated for a total of 18 rounds, after which reverse transcription produced 192 CC clones. One sequence was present in 168 of these clones. This sequence CC had a Kd of 10 nM and was used as starting sequence for preparation of CC optimised and truncated RNA aptamers or spiegelmers (RMs). Antagonists of CC CGRP, amylin and amyloid polypeptides are useful for treating and/or CC preventing: migraine, cluster headache, lack of appetite, nausea, CC vomiting, neurogenic inflammation (especially where mediated by other CC neuropeptides), vasodilation, hypo- or hyper-tension, tachycardia, CC diseases that are associated with activation of trigeminal afferent CC sensory neurons and central nociceptive neurons (especially of the higher CC pain centres and including chronic inflammatory pain) and/or pain CC generally (chronic, acute, inflammatory, visceral or neuropathic), where CC CGRP is the target and hypertension, diabetes, disorders of gastric CC emptying, diabetic gastroparesis and polydysia, where amylin or amyloid CC peptides are the target. Antagonists that are nucleic acids are also CC useful for detecting CGRP, amylin and amyloid polypeptides or plaques, to CC screen for other CGRP and amylin antagonists or agonists, as starting CC materials for rational drug design, for target validation and for CC studying CGRP or amylin function.

SQ Sequence 49 BP; 15 A; 8 C; 16 G; 0 T; 10 U; 0 Other;
Query Match 54.0%; Score 16.2; DB 11; Length 49;
Best Local Similarity 72.4%; Prd. No. 2.7e+03;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
Qy 2 TAATTCGCCAGAGAGATGTTCTGTC 30
Db 42 TCATCGTCCTAGAGATGTTCTTC 14

RESULT 11
ADM67858 standard; RNA; 49 BP.
ID ADM67858
XX AC ADM67858;
XX DT 03-JUN-2004 (first entry)
XX DE Rat alpha-D-CGRP binding oligonucleotide SEQ ID 101.
XX KW nucleic acid amplification; antimigraine; analgesic; l-nucleic acid;
KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
KW drug design; primer; ss.
XX OS Rattus sp.
XX PN WO200303504-A1.
XX 13-NOV-2003.
XX DE 06-MAY-2003; 2003WO-EP004747.
XX PR 06-MAY-2002; 2002DE-01020191.
XX (NOXX-) NOXXON PHARMA AG.
XX PI Vater A, Jarosch F, Wettich A, Klussmann S;
XX PA (NOXX-) NOXXON PHARMA AG.
XX PI Vater A, Jarosch F, Wettich A, Klussmann S;
XX DR 2003-854487/79.
XX PT Amplification of nucleic acid using two adaptors, useful for selection PT and preparation of aptamers, potential therapeutic agents, with all steps PT done in one vessel.
XX PS Example 12; SEQ ID NO 101; 262PP; German.

CC This invention describes a novel method for amplifying nucleic acids. The CC method comprises 1) preparing a target to be amplified, preferably RNA, CC having defined 5' and 3' sequences, separated by an intermediate CC sequence, 2) preparing a first adaptor (Ad1) of double stranded nucleic CC acid (especially one strand of RNA and the other DNA), where the 5'-end

of the DNA strand has an overhang at least partly complementary with the 5'-end of the target, 3) preparing a second adapter (Ad2) of double stranded nucleic acid, where the first strand has a 5'-phosphate residue on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at least partly complementary with the 3'-end of the target, the second strand also has a cleavage site which can generate a cleavage product that includes the complementary 3'-end of the second strand, 4) the adapters are ligated on the target, 5) reverse transcription is performed and optionally the second strand is synthesised. The products of the invention have antimigraine and analgesic activity. The method is especially used for selection and preparation of nucleic acids including L-nucleic acids, that bind to selected targets (aptamers), potentially useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin gene-related peptide) or amylin or their receptors, suitable for treatment of pain, migraine and other conditions, also as starting points for rational drug design, in screening for therapeutic compounds and for target validation. The method can be done in a single vessel, without purification of process intermediates and it can be applied to short sequences. ADM6779-ADM67903 represent oligoribonucleotides capable of binding to rat CGRP which are used to illustrate the method of the invention.

SQ Sequence 49 BP; 16 A; 9 C; 16 G; 0 T; 8 U; 0 Other;

Query Match 54.0%; Score 16.2%; DB 11; Length 49;
Best Local Similarity 72.4%; Pred. No. 2.7e+03;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATGGGGAAAGAGAGATGTTCTGTC 30
Db 42 TCATGGTCACAGAGCAATCTTTCCTTC 14

RESULT 12 ADM68137/C

ID ADM68137 standard; DNA; 49 BP.

XX

AC ADM68137;

XX DT 03-JUN-2004 (first entry)

XX DE Oligonucleotide STAR-R02-15xx-B10.

XX KW nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;

KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;

KW drug design; primer; ss.

XX OS Synthetic.

XX PN WO2003093504-A1.

XX PD 13-NOV-2003.

XX PF 06-MAY-2003; 2003WO-EP004747.

XX PR 06-MAY-2002; 2002DE-01020191.

XX PA (NOXX-) NOXXON PHARMA AG.

XX PI Vater A, Jarosch F, Wettlich A, Klussmann S;

XX DR WPI; 2003-854487/79.

XX Example 12; Fig 36; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The method comprises 1) preparing a target to be amplified, preferably RNA, having defined 5' and 3' sequences 2) preparing two adapters, useful for selection and preparation of aptamers, potential therapeutic agents, with all steps done in one vessel. Example 12; Fig 37; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The method comprises 1) preparing a target to be amplified, preferably RNA, having defined 5' and 3' sequences 2) preparing two adapters, useful for selection and preparation of aptamers, potential therapeutic agents, with all steps done in one vessel. Example 12; Fig 37; 262pp; German.

acid (especially one strand of RNA and the other DNA), where the 5'-end of the DNA strand has an overhang at least partly complementary with the 5'-end of the target, 3) preparing a second adapter (Ad2) of double stranded nucleic acid, where the first strand has a 5'-phosphate residue on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at least partly complementary with the 3'-end of the target, the second strand also has a cleavage site which can generate a cleavage product that includes the complementary 3'-end of the second strand, 4) the adapters are ligated on the target, 5) reverse transcription is performed and optionally the second strand is synthesised. The products of the invention have antimigraine and analgesic activity. The method is especially used for selection and preparation of nucleic acids including L-nucleic acids, that bind to selected targets (aptamers), potentially useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin gene-related peptide) or amylin or their receptors, suitable for treatment of pain, migraine and other conditions, also as starting points for rational drug design, in screening for therapeutic compounds and for target validation. The method can be done in a single vessel, without purification of process intermediates and it can be applied to short sequences. ADM6779-ADM67903 represent oligoribonucleotides capable of binding to rat CGRP which are used to illustrate the method of the invention.

SQ Sequence 49 BP; 15 A; 8 C; 16 G; 10 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2%; DB 11; Length 49;
Best Local Similarity 72.4%; Pred. No. 2.7e+03;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATGGGGAAAGAGAGATGTTCTGTC 30
Db 42 TCATGGTCACAGAGCAATCTTTCCTTC 14

RESULT 13 ADM6810/C

ID ADM68170 standard; DNA; 49 BP.

XX AC ADM68170;

XX DT 03-JUN-2004 (first entry)

XX DE Oligonucleotide STAR-R02-15xx-B10.

XX KW nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
KW drug design; primer; ss.

OS Synthetic.

XX PN WO2003093504-A1.

XX PD 13-NOV-2003.

XX PF 06-MAY-2003; 2003WO-EP004747.

XX PR 06-MAY-2002; 2002DE-01020191.

XX PA (NOXX-) NOXXON PHARMA AG.

XX PI Vater A, Jarosch F, Wettlich A, Klussmann S;

XX DR WPI; 2003-854487/79.

XX Example 12; Fig 36; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The method comprises 1) preparing a target to be amplified, preferably RNA, having defined 5' and 3' sequences 2) preparing two adapters, useful for selection and preparation of aptamers, potential therapeutic agents, with all steps done in one vessel. Example 12; Fig 37; 262pp; German.

CC of the DNA strand has an overhang at least partly complementary with the 5'-end of the target, 3) preparing a second adapter (Ad2) of double stranded nucleic acid, where the first strand has a 5'-phosphate residue on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at least partly complementary with the 3'-end of the target, the second strand also has a cleavage site which can generate a cleavage product that includes the complementary 3'-end of the second strand, 4) the CC adapters are ligated on the target, 5) reverse transcription is performed and optionally the second strand is synthesised. The products of the invention have antimigraine and analgesic activity. The method is especially used for selection and preparation of nucleic acids including L-nucleic acids, that bind to selected targets (aptamers), potentially useful as therapeutic agents, bind to selected targets (aptamers), e.g. as antagonists of CGRP (calcitonin gene-related peptide) or amylin or their receptors, suitable for treatment of pain, migraine and other conditions, also as starting points for rational drug design, in screening for therapeutic compounds and for target validation. The method can be done in a single vessel, without purification of process intermediates and it can be applied to short CC sequences.

XX Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Prd. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
 Qy 2 TAATTGGCCAAGAAATGGTTCTGTC 30
 Db 42 TCATCGTCCTAGCAATGTTCTTC 14

RESULT 14

ADM68130_c
ID ADM68130 standard DNA; 49 BP.

XX

AC ADM68130;

XX

DT 03-JUN-2004 (first entry)

XX Oligonucleotide STAR-R02-15d-E1.

XX

DE

RESULT 15

ADM7825_c
ID ADM67825 standard; RNA; 49 BP.

XX

AC ADM67825;

XX

DT 03-JUN-2004 (first entry)

XX

DE

XX

SQ Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Prd. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
 Qy 2 TAATTGGCCAAGAAATGGTTCTGTC 30
 Db 42 TCATCGTCCTAGCAATGTTCTTC 14

RESULT 16

ADM7825_c
ID ADM67825 standard; RNA; 49 BP.

XX

AC ADM67825;

XX

DT 03-JUN-2004 (first entry)

XX

DE

SQ Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Prd. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGGCCAAGAAATGGTTCTGTC 30

Db 42 TCATCGTCCTAGCAATGTTCTTC 14

RESULT 17

ADM7825_c
ID ADM7825 standard; RNA; 49 BP.

XX

AC ADM7825;

XX

DT 03-JUN-2004 (first entry)

XX

DE

SQ Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Prd. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGGCCAAGAAATGGTTCTGTC 30

Db 42 TCATCGTCCTAGCAATGTTCTTC 14

RESULT 18

ADM7825_c
ID ADM7825 standard; RNA; 49 BP.

XX

AC ADM7825;

XX

DT 03-JUN-2004 (first entry)

XX

DE

SQ Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Prd. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGGCCAAGAAATGGTTCTGTC 30

Db 42 TCATCGTCCTAGCAATGTTCTTC 14

RESULT 19

ADM7825_c
ID ADM7825 standard; RNA; 49 BP.

XX

AC ADM7825;

XX

DT 03-JUN-2004 (first entry)

XX

DE

SQ Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Prd. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGGCCAAGAAATGGTTCTGTC 30

Db 42 TCATCGTCCTAGCAATGTTCTTC 14

RESULT 20

ADM7825_c
ID ADM7825 standard; RNA; 49 BP.

XX

AC ADM7825;

XX

DT 03-JUN-2004 (first entry)

XX

DE

SQ Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Prd. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGGCCAAGAAATGGTTCTGTC 30

Db 42 TCATCGTCCTAGCAATGTTCTTC 14

RESULT 21

ADM7825_c
ID ADM7825 standard; RNA; 49 BP.

XX

AC ADM7825;

XX

DT 03-JUN-2004 (first entry)

XX

DE

SQ Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Prd. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGGCCAAGAAATGGTTCTGTC 30

Db 42 TCATCGTCCTAGCAATGTTCTTC 14

RESULT 22

ADM7825_c
ID ADM7825 standard; RNA; 49 BP.

XX

AC ADM7825;

XX

DT 03-JUN-2004 (first entry)

XX

stranded nucleic acid, where the first strand has a 5'-phosphate residue on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at least partly complementary with the 3'-end of the target, the second strand also has a cleavage site which can generate a cleavage product that includes the complementary 3'-end of the second strand, 4) the adaptors are ligated on the target, 5) reverse transcription is performed and optionally the second strand is synthesized. The products of the invention have antimigraine and analgesic activity. The method is especially used for selection and preparation of nucleic acids including L-nucleic acids, that bind to selected targets (aptamers), potentially useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin gene-related peptide) or amylin or their receptors, suitable for treatment of pain, migraine and other conditions, also as starting point for rational drug design, in screening for therapeutic compounds and for target validation. The method can be done in a single vessel, without purification of process intermediates and it can be applied to short sequences. AMD67759-AMD67903 represent oligoribonucleotides capable of binding to rat CGRP which are used to illustrate the method of the

Query	Match	Score	Length
Best Local Similarity	54.0%	16.2	49
Matches	72.4%	DB 11;	
21;	Conservative	Pred. No. 2.7e-03;	
		0; Mismatches 8;	
		Indels 0; Gaps 0;	

2 TAATTGGGCAAGAAGAAATTGTTCTGTC 30
42 TCACTCGTCACAAAGACGAATCGTTTCTTC 14

Search completed: November 5, 2004, 15:52:39
Job time : 347 secs



Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 15:29:17 ; Search time 71 Seconds

(without alignments)
300,333 Million cell updates/sec

Title: US-09-890-363-1

Perfect score: 30

Sequence: 1 gtaattgcggcaagaatgttgtctgtc 30

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 824507 seqs, 355394441 residues

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 75

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents_NA:*

1: /cgn2_6_ptodata/1/ina/5A_COMB.seq:*

2: /cgn2_6_ptodata/1/ina/5B_COMB.seq:*

3: /cgn2_6_ptodata/1/ina/6A_COMB.seq:*

4: /cgn2_6_ptodata/1/ina/6B_COMB.seq:*

5: /cgn2_6_ptodata/1/ina/9CTUS_COMB.seq:*

6: /cgn2_6_ptodata/1/ina/backfile1.seq:*

Pred. NO. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	17	56.7	43	4 US-09-627-746-17	Sequence 17, App1
C 2	15.8	52.7	41	3 US-08-813-307-94	Sequence 94, App1
C 3	15.8	52.7	41	3 US-09-464-53-94	Sequence 94, App1
C 4	15.8	52.7	47	4 US-09-671-317-510	Sequence 510, App1
C 5	15.2	50.7	75	3 US-09-105-30-25	Sequence 25, App1
C 6	14.8	49.3	47	4 US-09-671-317-596	Sequence 596, App1
C 7	14.8	49.3	73	1 US-08-134-001-42	Sequence 42, App1
C 8	14.8	49.3	73	1 US-08-133-385-42	Sequence 42, App1
C 9	14.8	49.3	73	1 US-08-434-425-42	Sequence 42, App1
C 10	14.8	49.3	73	2 US-08-437-667-42	Sequence 42, App1
C 11	14.8	49.3	73	3 US-08-906-955-42	Sequence 42, App1
C 12	14.8	49.3	73	3 US-08-945-909-42	Sequence 42, App1
C 13	14.8	49.3	73	3 US-09-396-002A-42	Sequence 42, App1
C 14	14.8	49.3	73	4 US-10-077-319-42	Sequence 42, App1
C 15	14.8	49.3	73	5 PCT-US96-06560-42	Sequence 14, App1
C 16	14.6	48.7	40	1 US-07-741-940-14	Sequence 14, App1
C 17	14.6	48.7	40	1 US-08-289-54A-14	Sequence 14, App1
C 18	14.6	48.7	40	1 US-08-452-655B-14	Sequence 14, App1
C 19	14.6	48.7	40	1 US-08-452-655B-14	Sequence 14, App1
C 20	14.6	48.7	40	3 US-08-150-587-14	Sequence 14, App1
C 21	14.6	48.7	40	4 US-08-449-731-14	Sequence 14, App1
C 22	14.4	48.0	57	4 US-09-270-757-29842	Sequence 29842, App1
C 23	14.4	48.0	61	3 US-19-215-850-56	Sequence 13, App1
C 24	14.2	47.3	27	3 US-09-237-584-13	Sequence 15, App1
C 25	14.1	46.7	24	3 US-09-186-170-15	Sequence 15, App1
C 26	14.1	46.7	24	4 US-09-522-866-15	Sequence 15, App1
C 27	14.1	46.7	24	4 US-10-116-288-15	Sequence 15, App1

ALIGNMENTS

C 28	14	46.7	27	3 US-09-186-170-16	Sequence 16, App1
C 29	14	46.7	27	4 US-10-116-288-16	Sequence 16, App1
C 30	14	46.7	30	3 US-09-186-170-17	Sequence 17, App1
C 31	14	46.7	30	4 US-09-186-288-17	Sequence 17, App1
C 32	14	46.7	30	4 US-10-116-288-17	Sequence 17, App1
C 33	14	46.7	33	3 US-09-186-170-14	Sequence 18, App1
C 34	14	46.7	33	3 US-09-186-170-18	Sequence 18, App1
C 35	14	46.7	33	4 US-09-186-288-14	Sequence 18, App1
C 36	14	46.7	33	4 US-09-186-288-18	Sequence 18, App1
C 37	14	46.7	33	4 US-09-186-288-18	Sequence 18, App1
C 38	14	46.7	33	4 US-10-116-288-14	Sequence 18, App1
C 39	14	46.7	33	4 US-10-116-288-18	Sequence 18, App1
C 40	14	46.7	36	4 US-09-186-170-10	Sequence 10, App1
C 41	14	46.7	36	4 US-09-186-288-10	Sequence 10, App1
C 42	14	46.7	36	4 US-10-116-288-10	Sequence 10, App1
C 43	14	46.7	47	4 US-09-380-190A-32	Sequence 3644, App1
C 44	13.8	46.0	23	4 US-09-502-240-13	Sequence 13, App1
C 45	13.8	46.0	23	4 US-09-502-240-13	Sequence 13, App1

RESULT 1

US-09-027-746-17/c

; Sequence 17, Application US/09627746

; Patent No. 6635475

; GENERAL INFORMATION:

; APPLICANT: Helmman, John

; TITLE OF INVENTION: *Bacillus subtilis Extracytoplasmic Function Sigma Factor*

; FILE REFERENCE: 10845-125

; CURRENT APPLICATION NUMBER: US/09-627-746

; CURRENT FILING DATE: 2000-07-28

; PRIOR APPLICATION NUMBER: US 60/146,466

; PRIOR FILING DATE: 1999-07-30

; NUMBER OF SEQ ID NOS: 21

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO: 17

; LENGTH: 43

; TYPE: DNA

; ORGANISM: *Bacillus subtilis*

; US-09-277-746-17

Query Match 56.7%; Score 17; DB 4; Length 43;

Best Local Similarity 80.0%; Pred. No. 97; Mismatches 0; Gaps 0;

Matches 20; Conservative 20; Index 5; Indels 0; Gaps 0;

Qy 2 TATTCGGCGAGAAGAGATTGTTTC 26

Db 31 TACGTGAGAAAGAGAAATGTTTC 7

RESULT 2

US-08-813-507-94

; Sequence 94, Application US/08813507

; Patent No. 6114116

; GENERAL INFORMATION:

; APPLICANT: Lemieux, Bertrand

; INVENTOR: Lalande, Benoit S.

; APPLICANT: Sapolsky, Ronald J.

; TITLE OF INVENTION: *Brassica Polymorphisms*

; NUMBER OF SEQUENCES: 173

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend and Crew LLP

; STREET: Two Embarcadero Center, Eighth Floor

; CITY: San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94111-3834

; COMPUTER READABLE FORM: 1

; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: DOS

COMPUTER READABLE FORM:

 MEDIUM TYPE: Diskette

 COMPUTER: IBM Compatible

 SOFTWARE: FastSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

 APPLICATION NUMBER: US/09/105,390

 FILING DATE: Filed herewith

 CLASSIFICATION:

 APPLICATION NUMBER: 60/050,675

 FILING DATE: 25-JUN-97

ATTORNEY/AGENT INFORMATION:

 NAME: Petthory, Joanne R.

 REGISTRATION NUMBER: P42,995

 REFERENCE/DOCKET NUMBER: 2000-0455.30

TELECOMMUNICATION INFORMATION:

 TELEPHONE: 650-324-0960

 TELEX:

 SEQUENCE CHARACTERISTICS:

 LENGTH: 75 base Pairs

 TYPE: nucleic acid

 STRANDDNESS: single

 TOPOLOGY: Linear

 NAME/KEY: Coding Sequence

 LOCATION: 1..75

 OTHER INFORMATION:

US-09-105,390-25

Query Match 50.7%; Score 15.2; DB 3; Length 75;

 Best Local Similarity 71.4%; Pred. No. 7.28+02; Mismatches 0;

 Matches 20; Conservative 0; Indels 0; Gaps 0;

Qy 1 GTAATGGGGAAAGAGAAATTGTTCTG 28

Db 59 GGAATGCTGAAGGAAATGCTACTG 32

RESULT 6

US-09-671-317-596

 Sequence 596, Application US/09671317

 Patent No. 6528260

GENERAL INFORMATION:

 APPLICANT: Blumenthal, Marta

 APPLICANT: Chunakov, Ilya

 APPLICANT: Bouquelert, Lydie

 APPLICANT: Cohen, Annick

 TITLE OF INVENTION: BIOTIPLIC MARKERS RELATED TO GENES INVOLVED IN DRUG METABOLISM

FILE REFERENCE: 62 US3-CTP

CURRENT APPLICATION NUMBER: US/09/671,317

PRIOR APPLICATION NUMBER: 2000-09-27

PRIOR FILING DATE: 2000-03-23

PRIOR APPLICATION NUMBER: PCT/IB00/00403

PRIOR FILING DATE: 2000-03-24

PRIOR APPLICATION NUMBER: US 60/126,269

PRIOR FILING DATE: 1999-03-25

PRIOR APPLICATION NUMBER: US 60/131,961

PRIOR FILING DATE: 1999-04-30

NUMBER OF SEQ ID NOS: 977

SOFTWARE: Patent. pm

SEQ ID NO 596

LENGTH: 47

TYPE: DNA

ORGANISM: Homo Sapiens

FEATURE: allele

LOCATION: 24

OTHER INFORMATION: 2-11-284 : polymorphic base A or G

US-09-671-317-596

Query Match 49.3%; Score 14.8; DB 4; Length 47;

 Best Local Similarity 80.0%; Pred. No. 9.9e+02; Mismatches 3; Indels 0; Gaps 0;

 Matches 16; Conservative 1; Indels 3; Gaps 0;

Qy 11 CAAGAGAAATTGTTCTGTC 30

Db 20 CAAGGAGATTTGCTATC 39

RESULT 7

US-08-434-001-42/c

 Sequence 42, Application US/08434001

 Patent No. 512375

GENERAL INFORMATION:

 APPLICANT: CHEN, HANG

 APPLICANT: MORRIS, KEVIN

 APPLICANT: STEPHENS, ANDREW

 APPLICANT: GOUD, LARRY

 APPLICANT: JENSEN, KIRK

 TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: TISSUE

 TITLE OF INVENTION: SELEX

 NUMBER OF SEQUENCES: 235

 CORRESPONDENCE ADDRESS:

 ADDRESSEE: Swanson & Bratschun, L.L.C.

 STREET: 8400 E. Prentice Avenue, Suite 200

 CITY: Englewood

 STATE: Colorado

 COUNTRY: USA

 ZIP: 80111

COMPUTER READEABLE FORM:

 MEDIUM TYPE: Disquette, 3 1/2 diskette, 1.44 MB

 COMPUTER: IBM PC compatible

 OPERATING SYSTEM: MS-DOS

 SOFTWARE: WordPerfect 5.1

 CURRENT APPLICATION DATA:

 APPLICATION NUMBER: US/08/434,001

 FILING DATE:

 CLASSIFICATION: 435

PRIOR APPLICATION DATA:

 APPLICATION NUMBER: 07/714,131

 FILING DATE: 10-JUNE-1991

PRIOR APPLICATION DATA:

 APPLICATION NUMBER: 07/536,428

 FILING DATE: 11-JUNE-1990

PRIOR APPLICATION DATA:

 APPLICATION NUMBER: 07/964,624

 FILING DATE: 21-OCTOBER-1992

ATTORNEY/AGENT INFORMATION:

 NAME: Barry J. Swanson

REGISTRATION NUMBER: 33,215

REFERENCE/DOCKET NUMBER: NX30.3

TELECOMMUNICATION INFORMATION:

 TELEPHONE: (303) 793-3333

 TELEFAX: (303) 793-3433

 INFORMATION FOR SEQ ID NO: 42:

SEQUENCE CHARACTERISTICS:

 LENGTH: 73 base Pairs

 TYPE: nucleic acid

 STRANDEDNESS: single

 TOPOLOGY: Linear

US-08-434-001-42

Query Match 49.3%; Score 14.8; DB 1; Length 73;

 Best Local Similarity 73.1%; Pred. No. 1.1e+03; Mismatches 0; Indels 0; Gaps 0;

 Matches 19; Conservative 0; Indels 0; Gaps 0;

Qy 3 AATGGCCAAAGAAATTGTTCTG 28

Db 55 AAAGCACAAAGATGGTTGG 30

RESULT 8
 US-08-43-585-42/C
 Sequence 42, Application US/08433585
 Patent No. 576356
 GENERAL INFORMATION:
 APPLICANT: JENSEN, KIRK
 APPLICANT: CHEN, HANG
 APPLICANT: MORRIS, KEVIN
 APPLICANT: STEPHENS, ANDREW
 APPLICANT: GOLD, LARRY
 TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: TISSUE
 TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: TISSUE
 NUMBER OF SEQUENCES: 235
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Swanson & Bratschun, L.L.C.
 STREET: 8400 E. Prentice Avenue, Suite 200
 CITY: Englewood
 STATE: Colorado
 COUNTRY: USA
 ZIP: 80111
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
 COMPUTER: IBM pc compatible
 OPERATING SYSTEM: MS-DOS
 SOFTWARE: Wordperfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/433,585
 FILING DATE:
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 07/714,131
 FILING DATE: 10-JUNE-1991
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 07/536,428
 FILING DATE: 11-JUNE-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 07/964,624
 FILING DATE: 21-OCTOBER-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Barry J. Swanson
 REGISTRATION NUMBER: 33,215
 REFERENCE/DOCKET NUMBER: NEX30.1
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (303) 793-3333
 TELEFAX: (303) 793-3433
 INFORMATION FOR SEQ ID NO: 42:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 73 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-433-585-42

RESULT 10
 US-08-437-667-42/C
 Sequence 42, Application US/08437667
 Patent No. 5,864,016
 GENERAL INFORMATION:
 APPLICANT: JENSEN, KIRK
 APPLICANT: CHEN, HANG
 APPLICANT: MORRIS, KEVIN
 APPLICANT: STEPHENS, ANDREW
 APPLICANT: GOLD, LARRY
 TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: TISSUE
 TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: TISSUE
 NUMBER OF SEQUENCES: 235
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Swanson & Bratschun, L.L.C.
 STREET: 8400 E. Prentice Avenue, Suite 200
 CITY: Englewood
 STATE: Colorado
 COUNTRY: USA

RESULT 9
 US-08-434-425-42/C
 Sequence 42, Application US/08434425
 Patent No. 5789157
 GENERAL INFORMATION:
 APPLICANT: JENSEN, KIRK
 APPLICANT: CHEN, HANG
 APPLICANT: MORRIS, KEVIN
 APPLICANT: STEPHENS, ANDREW
 APPLICANT: GOLD, LARRY

Query Match 49.3% Score 14.8; DB 1; Length 73;
 Best Local Similarity 72.1%; Prod. No. 1.1e+03; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 3 AATTCGGGAAAGAAGAATGTTCTG 28
 Db 55 AATACGAGAAGAATAGGTTTCGG 30

Query Match 49.3% Score 14.8; DB 1; Length 73;
 Best Local Similarity 73.1%; Prod. No. 1.1e+03; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 3 AATTCGGGAAAGAAGAATGTTCTG 28
 Db 55 AATACGAGAAGAATAGGTTTCGG 30

RESULT 10
 US-08-437-667-42/C
 Sequence 42, Application US/08437667
 Patent No. 5,864,016
 GENERAL INFORMATION:
 APPLICANT: JENSEN, KIRK
 APPLICANT: CHEN, HANG
 APPLICANT: MORRIS, KEVIN
 APPLICANT: STEPHENS, ANDREW
 APPLICANT: GOLD, LARRY

Query Match 49.3% Score 14.8; DB 1; Length 73;
 Best Local Similarity 72.1%; Prod. No. 1.1e+03; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 3 AATTCGGGAAAGAAGAATGTTCTG 28
 Db 55 AATACGAGAAGAATAGGTTTCGG 30

```

; ZIP: 80111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
; COMPUTER: IBM pc compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION NUMBER: US/08/437,667
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/714,131
; FILING DATE: 10-JUNE-1991
; PRIOR APPLICATION DATA:
; NAME: Barry J. Swanson
; REGISTRATION NUMBER: 33,215
; FILING DATE: 11-JUNE-1990
; REFERENCE/DOCKET NUMBER: NEX30-2
; APPLICATION NUMBER: 07/964,624
; FILING DATE: 21-OCTOBER-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Barry J. Swanson
; REGISTRATION NUMBER: 33,215
; FILING DATE: 11-JUNE-1990
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 793-3433
; TELEFAX: (303) 793-3433
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 73 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: Single
; TOPOLOGY: linear
; US-08-437,667-42

; RESULT 11
; US-08-906-955-42/C
; Sequence 42, Application US/08906955
; Patent No. 6013443
; GENERAL INFORMATION:
; APPLICANT: HEILIG, JOSEPH S.
; APPLICANT: GOLDE, LARRY
; TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
; TITLE OF INVENTION: EXPONENTIAL ENRICHMENT: TISSUE
; TITLE OF INVENTION: SELLEX
; NUMBER OF SEQUENCES: 240
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Swanson & Bratschun, L.L.C.
; STREET: 8400 E. Prentice Avenue, Suite 200
; CITY: Englewood
; STATE: Colorado
; COUNTRY: USA
; ZIP: 80111

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
; COMPUTER: IBM pc compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/906,955
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/714,131
; FILING DATE: 10-JUNE-1991

; RESULT 12
; US-08-945-309-42/C
; Sequence 42, Application US/08945909
; Patent No. 6114120
; GENERAL INFORMATION:
; APPLICANT: JENSEN, KIRK
; APPLICANT: CHEN, HANG
; APPLICANT: MORRIS, KEVIN
; APPLICANT: STEPHENS, ANDREW
; APPLICANT: GOLD, LARRY
; APPLICANT: GOLDE, LARRY
; TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS
; TITLE OF INVENTION: ENRICHMENT: TISSUE SELLEX
; NUMBER OF SEQUENCES: 240
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Swanson & Bratschun, L.L.C.
; STREET: 8400 E. Prentice Avenue, Suite 200
; CITY: Englewood
; STATE: Colorado
; COUNTRY: USA
; ZIP: 80111

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
; COMPUTER: IBM pc compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/945,909
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/06060
; FILING DATE: 01-MAY-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/434,425
; FILING DATE: 03-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/437,667
; FILING DATE: 03-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/434,001
; FILING DATE: 03-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/433,585
; FILING DATE: 03-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Barry J. Swanson

```

REGISTRATION NUMBER: 33,215
 REFERENCE/DOCKET NUMBER: NEX30C-US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (303) 793-3333
 INFORMATION FOR SEQ ID NO: 42:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 73 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-945-909-42

Query Match 49.3% Score 14.8; DB 3; Length 73;
 Best Local Similarity 73.1%; Prod. No. 1.1e+03; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 3 AATGGCGGAAGAGAATGGTTCTG 28
 Db 55 AATAGCAGCAAGAAATAGGTTCGG 30

RESULT 14
 US-10-077-319-42/C
 ; Sequence 42, Application US/10077319
 ; Patent No. 661326
 ; GENERAL INFORMATION:
 ; APPLICANT: HELIG, JOSEPH S.
 ; GOLD, LARRY
 ; TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
 ; EXPONENTIAL ENRICHMENT: TISSUE SELEX
 ; NUMBER OF SEQUENCES: 240
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Swanson & Bratschun, L.L.C.
 ; STREET: 1745 Shea Center Drive, Suite 330
 ; CITY: Highlands Ranch
 ; STATE: Colorado
 ; COUNTRY: USA
 ; ZIP: 80129

COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
 COMPUTER: IBM pc compatible
 OPERATING SYSTEM: MS-DOS
 SOFTWARE: WordPerfect 8.0

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/10/077,319
 FILING DATE: 14-Feb-2002
 CLASSIFICATION: <Unknown>
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 09/396,002
 FILING DATE: 14-Sep-1999
 APPLICATION NUMBER: US/10/077,319
 FILING DATE: 14-Feb-2002
 ATTORNEY/AGENT INFORMATION:
 NAME: Barry J. Swanson
 REGISTRATION NUMBER: 33,215
 REFERENCE/DOCKET NUMBER: NEX30-5/D
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (303) 268-0065
 INFORMATION FOR SEQ ID NO: 42:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 73 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 SEQUENCE DESCRIPTION: SEQ ID NO: 42:
 US-10-077-319-42

Query Match 49.3% Score 14.8; DB 4; Length 73;
 Best Local Similarity 73.1%; Prod. No. 1.1e+03; Indels 0; Gaps 0;

Qy 3 AATGGCGGAAGAGAATGGTTCTG 28
 Db 55 AATAGCAGCAAGAAATAGGTTCGG 30

RESULT 15
 PCT-US96-06060-42/C
 ; Sequence 42, Application PC/TUSS9606060
 ; GENERAL INFORMATION:
 ; APPLICANT: JENSEN, KIRK
 ; APPLICANT: CHEN, HANG

US-09-396-002A-42:
 Query Match 49.3% Score 14.8; DB 3; Length 73;
 Best Local Similarity 73.1%; Prod. No. 1.1e+03;

APPLICANT: MORRIS, KEVIN
 APPLICANT: STEPHENS, ANDREW
 APPLICANT: GOLD, LARRY
 TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
 EXPONENTIAL ENRICHMENT: TISSUE
 NUMBER OF SEQUENCES: 240
 TITLE OF INVENTION: SELEX
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Swanson & Bratschun, L.L.C.
 STREET: 800 E. Prentice Avenue, Suite 200
 CITY: Englewood
 STATE: Colorado
 COUNTRY: USA
 ZIP: 80111
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: MS DOS
 SOFTWARE: Wordperfect 5.1
 APPLICATION NUMBER: PCT/US96/06060
 FILING DATE:
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 07/714,131
 FILING DATE: 10-JUNE-1991
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 07/536,428
 FILING DATE: 11-JUNE-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 07/964,624
 FILING DATE: 21-OCTOBER-1992
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/434,425
 FILING DATE: 05-MAY-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/437,667
 FILING DATE: 05-MAY-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/434,001
 FILING DATE: 05-MAY-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/433,585
 FILING DATE: 05-MAY-1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Barry J. Swanson
 REGISTRATION NUMBER: 33,215
 REFERENCE/DOCKET NUMBER: NEX30/PCT
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (303) 793-3333
 TELEFAX: (303) 793-3433
 INFORMATION FOR SEQ ID NO: 42:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 73 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 PCT-US96-06060-42

Query Match 49.3%; Score 14.8; DB 5; Length 73;
 Best Local Similarity 73.1%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
 Qy 3 AATTGGCGCAAGAGAATTTCTG 28
 Db 55 ATTAGCGAAAGAAATAGGGTTGG 30

Search completed: November 5, 2004, 17:15:09
 Job time : 73 secs



GenCore version 5.1.6
(c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 15:47:02 ; Search time 344 Seconds

(without alignments)

469.545 Million cell updates/sec

Title: US-09-890-363-1

Perfect score: 30

Sequence: 1 gtaatggcaagaatgtttatgtc 30

Scoring table: IDENTITY_NUC

GapOp 11.0 , GapExt 1.0

Searched: 3611042 seqs, 2692057975 residues

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 75

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications NA.*

1: /cgn2_6_ptodata/1/pubpna/us07_pubcomb.seq*

2: /cgn2_6_ptodata/1/pubpna/pct_new_pub.seq*

3: /cgn2_6_ptodata/1/pubpna/us06_new_pub.seq*

4: /cgn2_6_ptodata/1/pubpna/us06_pubcomb.seq*

5: /cgn2_6_ptodata/1/pubpna/us07_new_pub.seq*

6: /cgn2_6_ptodata/1/pubpna/pctus07_pubcomb.seq*

7: /cgn2_6_ptodata/1/pubpna/us08_new_pub.seq*

8: /cgn2_6_ptodata/1/pubpna/us09_pubcomb.seq*

9: /cgn2_6_ptodata/1/pubpna/us09_pubcomb.seq*

10: /cgn2_6_ptodata/1/pubpna/us09_pubcomb.seq*

11: /cgn2_6_ptodata/1/pubpna/us09_new_pub.seq*

12: /cgn2_6_ptodata/1/pubpna/us10_pubcomb.seq*

13: /cgn2_6_ptodata/1/pubpna/us10_pubcomb.seq*

14: /cgn2_6_ptodata/1/pubpna/us10c_pubcomb.seq*

15: /cgn2_6_ptodata/1/pubpna/us10d_pubcomb.seq*

16: /cgn2_6_ptodata/1/pubpna/us10e_pubcomb.seq*

17: /cgn2_6_ptodata/1/pubpna/us10f_pubcomb.seq*

18: /cgn2_6_ptodata/1/pubpna/us10_new_pub.seq*

19: /cgn2_6_ptodata/1/pubpna/us11_new_pub.seq*

20: /cgn2_6_ptodata/1/pubpna/us00_pubcomb.seq*

21: /cgn2_6_ptodata/1/pubpna/us00_pubcomb.seq*

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No. Score Query Match Length DB ID Description

1 16.2 54.0 60 10 US-09-908-975-8004 Sequence 8004, AD

2 15.8 52.7 41 14 US-10-031-890-33 Sequence 94, App1

c 3 15.8 52.7 47 16 US-10-031-934-10 Sequence 510, App

4 15.4 51.3 43 15 US-10-032-585-769 Sequence 1769, App

5 15.4 51.3 65 10 US-09-908-975-30222 Sequence 30222, A

c 6 15.2 50.7 73 16 US-10-031-890-33 Sequence 33, App1

c 7 15.2 50.7 73 16 US-10-035-833A-2017 Sequence 2017, App

c 8 15.0 50.0 41 16 US-10-035-833A-46 Sequence 4012, App

c 9 15.0 50.0 68 13 US-10-027-632-51852 Sequence 51852, A

10 15.0 50.0 68 13 US-10-027-632-51860 Sequence 51860, A

11 15.0 50.0 68 15 US-10-027-632-51852 Sequence 51852, A

12 15.0 50.0 68 15 US-10-027-632-51852 Sequence 51852, A

Sequence 51860, A
Sequence 68, App1
Sequence 1755, App
Sequence 596, App
Sequence 1549, App
Sequence 1577, App
Sequence 42, App1
Sequence 49, App1
Sequence 3912, App
Sequence 24143, A
Sequence 26971, A
Sequence 2629, App
Sequence 56, App1
Sequence 199, App1
Sequence 48, App1
Sequence 2, App1
Sequence 7658, App
Sequence 2846, A
Sequence 1219, A
Sequence 12670, A
Sequence 13972, A
Sequence 15633, A
Sequence 22515, A
Sequence 1807, App
Sequence 28469, A
Sequence 4, App1
Sequence 5, App1
Sequence 6, App1
Sequence 7, App1
Sequence 15, App1
Sequence 12253, A
Sequence 16, App1
Sequence 17, App1
Sequence 14, App1
RESULT 1 US-09-908-975-8004 ; Sequence 8004, Application US/09908975 ; Publication No. US2003016593A1
GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
; TITLE OF INVENTION: THAT POPULATE A TRANSCRIPTOME
; FILE REFERENCE: 36688-1005
; CURRENT APPLICATION NUMBER: US/09/908-975
; PRIORITY APPLICATION NUMBER: 2001-07-20
; PRIORITY FILING DATE: 2001-05-02
; PRIORITY APPLICATION NUMBER: US 60/221, 607
; PRIORITY FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 8004
; LENGTH: 60
; TYPE: DNA
; ORGANISM: HOMO sapiens
Query Match Score 16.2; DB 10; Length 60;
Matches 18; Conservative 85.%; Pre. No. 2.9e+03; Indels 0; Gaps 0;
Qy 3 ATTCGCCAACAGAACATGTT 23
Db 29 AACTGCCAACAGAACATGTT 49

RESULT 2
 US-10-043-573-94
 / Sequence 94, Application US/10043573
 / Publication No. US200300320251
 / GENERAL INFORMATION:
 / / APPLICANT: Lemireux, Bertrand
 / / Landry, Benoit S.
 / / Sabolsky, Ronald J.
 / / TITLE OF INVENTION: Brassica Polymorphisms
 / / NUMBER OF SEQUENCES: 173
 / / CORRESPONDENCE ADDRESS:
 / / ADDRESSEE: Townsend and Townsend and Crew LLP
 / / STREET: Two Embarcadero Center, Eighth Floor
 / / CITY: San Francisco
 / / COUNTRY: USA
 / / ZIP: 94111-3834
 / / COMPUTER READABLE FORM:
 / / MEDIUM TYPE: Diskette
 / / COMPUTER: IBM Compatible
 / / OPERATING SYSTEM: DOS
 / / SOFTWARE: FastSEQ for Windows Version 2.0
 / / CURRENT APPLICATION DATA:
 / / APPLICATION NUMBER: US/10/043, 573
 / / FILING DATE: 09-Jan-2002
 / / CLASSIFICATION: <Unknown>
 / / PRIOR APPLICATION DATA:
 / / APPLICATION NUMBER: US/08/813, 507
 / / FILING DATE: 07-MAR-1997
 / / APPLICATION NUMBER: US 60/032, 069
 / / FILING DATE: 02-DEC-1996
 / / ATTORNEY/AGENT INFORMATION:
 / / NAME: Liebeschuetz, Joe
 / / REGISTRATION NUMBER: 37, 505
 / / TELECOMMUNICATION INFORMATION:
 / / TELEPHONE: 415 576-0200
 / / TELEFAX: 415 576-0200
 / / TELE: <Unknown>
 / / INFORMATION FOR SEQ ID NO: 94:
 / / SEQUENCE CHARACTERISTICS:
 / / LENGTH: 41 base pairs
 / / STRANDEDNESS: Single
 / / TOPOLOGY: Linear
 / / SEQUENCE DESCRIPTION: SEQ ID NO: 94:
 / / US-10-043-573-94

Query Match 52.7%; Score 15.8; DB 14; Length 41;
 * Best Local Similarity 74.1%; Pred. No. 4e-03;
 * Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
 Qy 4 ATTGGGGCAAGAAAGATTGTTCTCTC 30
 Db 12 ATTGGGTCTGATGGATTGTTCTATC 38

RESULT 3
 US-10-294-934-510/c
 / Sequence 510, Application US/10294934
 / Publication No. US2004003831A1
 / GENERAL INFORMATION:
 / / APPLICANT: Blumenfeld, Marta
 / / APPLICANT: Chumakov, Ilya
 / / APPLICANT: Boughner, Lydie
 / / APPLICANT: Cohen, Annick
 / / TITLE OF INVENTION: BIALLERIC MARKERS RELATED TO GENES INVOLVED IN DRUG METABOLISM
 / / FILE REFERENCE: 62.US.DIV
 / / CURRENT APPLICATION NUMBER: US/10/294, 934
 / / CURRENT FILING DATE: 2000-09-27
 / / PRIOR APPLICATION NUMBER: US 09/671, 317
 / / PRIOR FILING DATE: 2000-09-27

RESULT 4
 US-10-294-934-510
 / / Prior Application Number: US 09/536, 178
 / / Prior Filing Date: 2000-03-23
 / / Prior Application Number: PC7/IB00/00403
 / / Prior Filing Date: 2000-03-24
 / / Prior Application Number: US 60/126, 269
 / / Prior Filing Date: 1999-03-25
 / / Prior Application Number: US 60/131, 961
 / / Number of SEQ ID Nos: 977
 / / Software: Patent.pm
 / / SEQ ID NO: 510
 / / LENGTH: 47
 / / TYPE: DNA
 / / Organism: Homo Sapiens
 / / Feature:
 / / Name/Key: allele
 / / Location: 24
 / / OTHER INFORMATION: 12-456-269 : polymorphic base A or G
 / / US-10-294-934-510

Query Match 52.7%; Score 15.8; DB 16; Length 47;
 Best Local Similarity 74.1%; Pred. No. 4.1e+03;
 Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
 Qy 3 AATTGGGGAGAGAATGGTCTGT 29
 Db 30 AATTCYGTAGAGAATCCCTGCTC 4

RESULT 5
 US-10-032-585-1769
 / Sequence 1769, Application US/10032585
 / Publication No. US20030180953A1
 / GENERAL INFORMATION:
 / / APPLICANT: Terry, Roemer D.
 / / APPLICANT: Bo, Jiang
 / / APPLICANT: Charles, Boone
 / / APPLICANT: Howard, Bussey
 / / TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
 / / FILE REFERENCE: 10182-005-999
 / / CURRENT APPLICATION NUMBER: US/10/032, 585
 / / CURRENT FILING DATE: 2001-12-30
 / / NUMBER OF SEQ ID NOS: 8000
 / / SOFTWARE: PatentIn version 3.1
 / / SEQ ID NO: 1769
 / / LENGTH: 43
 / / TYPE: DNA
 / / Organism: Candida albicans
 / / US-10-032-585-1769

Query Match 51.3%; Score 15.4; DB 15; Length 43;
 Best Local Similarity 76.0%; Pred. No. 6e+03;
 Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 Qy 5 TTGGCCAGAGATGTTCTGT 29
 Db 1 TTACGCAAGACATGAACTAT 25

CURRENT FILING DATE: 2001-07-20
 PRIOR APPLICATION NUMBER: US 60/287,724
 PRIOR FILING DATE: 2001-05-02
 PRIOR APPLICATION NUMBER: US 60/221,607
 PRIOR FILING DATE: 2000-07-28
 NUMBER OF SEQ ID NOS: 32337
 SOFTWARE: PatentIn version 3.0
 SEQ ID NO: 30222
 LENGTH: 65
 TYPE: DNA
 ORGANISM: *Mus musculus*
 US-09-908-975-30222

Query Match 51.3%; Score 15.4; DB 10; Length 65;
 Best Local Similarity 76.0%; Pred. No. 6.6e+03;
 Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 2 TAATGGCCAAAGAGAAATGGTTC 26
 Db 16 TAACTGGACAGGGAGATCGTTTC 40

RESULT 6

US-10-403-337-33/c
 Sequence 33, Application US/10403337
 Publication No. US20010215948A1
 GENERAL INFORMATION:
 APPLICANT: Kaleko, Michael
 APPLICANT: Nemew, Glen R.
 APPLICANT: Smith, Theodore
 APPLICANT: Stevenson, Susan C.
 TITLE OF INVENTION: Fiber Shaft Modifications for Efficient Targeting
 FILE REFERENCE: 22908-12365
 CURRENT APPLICATION NUMBER: US/10/403,337
 CURRENT FILING DATE: 2003-03-27
 PRIOR FILING DATE: 2003-01-24
 PRIOR APPLICATION NUMBER: 6/351,890
 PRIOR FILING DATE: 2002-01-24
 PRIOR APPLICATION NUMBER: 60/391,967
 PRIOR FILING DATE: 2002-06-26
 NUMBER OF SEQ ID NOS: 72
 SOFTWARE: PatentIn version 3.0
 SEQ ID NO: 33
 LENGTH: 73
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE: OTHER INFORMATION: amplification primer
 US-10-403-337-33

Query Match 50.7%; Score 15.2; DB 15; Length 73;
 Best Local Similarity 71.4%; Pred. No. 8.4e+03;
 Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

RESULT 7

US-10-351-890-33/c
 Sequence 33, Application US/10351890
 Publication No. US20040002060A1
 GENERAL INFORMATION:
 APPLICANT: Kaleko, Michael
 APPLICANT: Smith, Theodore
 APPLICANT: Nemew, Glen R.
 TITLE OF INVENTION: Fiber Shaft Modifications for Efficient Targeting
 FILE REFERENCE: 22908-1236
 CURRENT APPLICATION NUMBER: US/10/351,890
 SEQ ID NO: 4612
 LENGTH: 41
 TYPE: DNA
 ORGANISM: Homo sapiens
 US-10-035-833A-4612

Query Match 50.7%; Score 15.2; DB 15; Length 73;
 Best Local Similarity 71.4%; Pred. No. 8.4e+03;
 Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
 QY 2 TAATGGCCAAAGAGAAATGGTTC 29
 Db 59 TAACTGAGATAAAGAATCGTTTGTT 32

Query Match 50.7%; Score 15.2; DB 15; Length 73;
 Best Local Similarity 71.4%; Pred. No. 8.4e+03;
 Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
 QY 2 TAATGGCCAAAGAGAAATGGTTC 29
 Db 59 TAACTGAGATAAAGAATCGTTTGTT 32

PRIOR APPLICATION NUMBER: 60/350,388
 PRIOR FILING DATE: 2002-01-24
 PRIOR APPLICATION NUMBER: 60/391,967
 PRIOR FILING DATE: 2002-06-26
 NUMBER OF SEQ ID NOS: 72
 SOFTWARE: PatentIn version 3.0
 SEQ ID NO: 33
 LENGTH: 73
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE: OTHER INFORMATION: amplification primer
 US-10-351-890-33

Query Match 50.7%; Score 15.2; DB 16; Length 73;
 Best Local Similarity 71.4%; Pred. No. 8.4e+03;
 Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
 QY 2 TAATGGCCAAAGAGAAATGGTTC 29
 Db 59 TAACTGAGATAAAGAATCGTTTGTT 32

RESULT 8

US-10-035-833A-2017/c
 Sequence 2017, Application US/10035833A
 Publication No. US20040072156A1
 GENERAL INFORMATION:
 APPLICANT: Nakamura, Yuho
 APPLICANT: Sekine, Akihiro
 APPLICANT: Saito, Osamu
 APPLICANT: Saito, Aritoshi
 TITLE OF INVENTION: Detection of Genetic Polymorphisms
 FILE REFERENCE: F0RS-05904
 CURRENT APPLICATION NUMBER: US/10/035,833A
 CURRENT FILING DATE: 2001-12-27
 NUMBER OF SEQ ID NOS: 7669
 SOFTWARE: PatentIn version 3.2
 SEQ ID NO: 2017
 LENGTH: 41
 TYPE: DNA
 ORGANISM: Homo sapiens
 US-10-035-833A-2017

Query Match 50.0%; Score 15; DB 16; Length 41;
 Best Local Similarity 72.0%; Pred. No. 9e+03;
 Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
 QY 2 TAATGGCCAAAGAGAAATGGTTC 26
 Db 38 TATTACAGGATATGAWTTTTTC 14

Query Match 50.0%; Score 15; DB 16; Length 41;
 Best Local Similarity 72.0%; Pred. No. 9e+03;
 Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
 QY 2 TAATGGCCAAAGAGAAATGGTTC 26
 Db 38 TATTACAGGATATGAWTTTTTC 14

Query Match 50.0%; Score 15; DB 16; Length 41;
 Best Local Similarity 72.0%; Pred. No. 9e+03;
 Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
 QY 2 TAATGGCCAAAGAGAAATGGTTC 26
 Db 38 TATTACAGGATATGAWTTTTTC 14

Query Match 50.0%; Score 15; DB 16; Length 41;
 Best Local Similarity 72.0%; Pred. No. 9e+03;
 Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
 QY 2 TAATGGCCAAAGAGAAATGGTTC 26
 Db 38 TATTACAGGATATGAWTTTTTC 14


```

; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/195,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: US 60/145,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 51860
; LENGTH: 68
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-31860

Query Match Score 15; DB 15; Length 68;
Best Local Similarity 72.0%; Pred. No. 1.e+04;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
Job time : 347 secs

Qy 2 TAATTGGCCAGAAAGAATTGTTTC 26
Db 10 TAATGGCATAAGAACSATTC 34

RESULT 14
US-10-125-994A-68
Sequence 68, Application US10125994A
Publication No. US20030203427A1
GENERAL INFORMATION:
; APPLICANT: Koike, Chihiro
; TITLE OF INVENTION: ALPHA 1, 3-GALACTOSYLTRANSFERASE GENE AND PROMOTER
; FILE REFERENCE: 206779
CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: PCT/US00/29139
; PRIOR FILING DATE: 2000-10-00
; PRIOR APPLICATION NUMBER: US 60/227,951
; PRIOR FILING DATE: 2000-09-25
; PRIOR FILING DATE: 1999-10-22
; NUMBER OF SEQ ID NOS: 96
; SOFTWARE: Patentin version 3.0
; SEQ ID NO: 68
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer for identifying murine exons 2 and 3
US-10-125-994A-68

Query Match Score 14.8%; DB 15; Length 35;
Best Local Similarity 73.1%; Pred. No. 1.1e+04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
Job time : 347 secs

Qy 5 TGGGGCAGAAAGAATGTTCTGTC 30
Db 6 TGGGGTCCAACTTCTGAC 31

RESULT 15
US-10-032-585-1755/c
; Sequence 1755, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.

```



GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 15:28:19 (without alignments)
472.221 Million cell updates/sec

Perfect score: 30

Scoring table: IDENTITY_NUC

Gapext 1.0

searched: 32822875 seqs, 18219865908 residues

Total number of hits satisfying chosen parameters: 389094

Minimum DB seq length: 0
Maximum DB seq length: 75

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST*
1: 9b_est1: *
2: 9b_est2: *
3: 9b_htc: *
4: 9b_est3: *
5: 9b_est4: *
6: 9b_est5: *
7: 9b_est6: *
8: 9b_gss1: *
9: 9b_gss2: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Score	Match	Length	DB	ID	Description
1	17.4	58.0	37	8	A233195	A233195_1M06G09	
2	15.6	52.0	70	1	T87927	T87927_Ye08C07_r1	
3	15.4	51.3	62	1	AL024389	AL024389_r8421a45	
4	15.4	51.3	67	1	AA591826	AA591826_v14e12_r	
5	15.4	51.3	70	8	CD881194	CD881194_F1-104K17	
6	15.4	51.3	70	8	BB865903	BB865903_SALK1000	
7	15.4	51.3	75	1	AU14056	AU14056_AU14056	
8	15.2	50.7	39	1	BB109815	BB109815_SALK0561	
9	15.2	50.7	49	9	AU759937	AU759937_Arabbidops	
10	15.2	50.7	74	1	AA70441	AA70441_zj21h01_5	
11	15.2	50.7	74	1	CP853347	CP853347_PSMC008X	
12	15	50.0	41	8	BB856306	BB856306_SALK0799	
13	15	50.0	58	1	AA554039	AA554039_nk95j3_s	
14	15	50.0	75	4	BM341762	BM341762_Fw52e08_y	
15	14.8	49.3	39	2	BB335115	BB335115_601231231	
16	14.8	49.3	44	8	AZ622559	AZ622559_1M045P24	
17	14.8	49.3	59	8	BZ769592	BZ769592_SALK1424	
18	14.8	49.3	60	1	AA388795	AA388795_vb25c07_r	
19	14.8	49.3	61	1	A1829969	A1829969_N23930_y8	
20	14.8	49.3	63	7	N22930	N22930_NF057603D	
21	14.6	48.7	52	2	BF633547	BF633547_BH812420	
22	14.6	48.7	54	8	BH812420	BH812420_SALK0617	
23	14.6	48.7	62	8	CG657820	CG657820_OST45327	
24	14.6	48.7	64	4	BI097338	BI097338_SW03NCAM	

ALIGNMENTS

c	25	14.6	48.7	67	9	CC795622	SALK_0875
	26	14.6	48.7	69	6	CD028582	rgns007xf
	27	14.6	48.7	72	4	BJ057828	BJ057828
c	28	14.6	48.7	73	5	BX697533	BX697533
c	29	14.6	48.7	73	5	CB832531	SWbmcEAV
c	30	14.6	48.7	73	9	CG495277	CG495277
c	31	14.6	48.7	74	7	CNB6295	0009034AL
c	32	14.6	48.7	75	2	AW247813	AW24477.3
c	33	14.4	48.0	42	1	AU268709	AU268709
c	34	14.4	48.0	45	6	CA967668	CC1L03A0
c	35	14.4	48.0	45	6	AV52289	AV52289
c	36	14.4	48.0	68	8	A222156	1006030CO
c	37	14.4	48.0	73	5	BU870947	BQ21E02_P
c	38	14.4	48.0	74	8	A2576247	AST-TD14S
c	39	14.4	48.0	75	6	CD744649	CD744649
c	40	14.2	47.3	37	4	BJ066419	BJ066419
c	41	14.2	47.3	50	8	BZ664415	SALK_0710
c	42	14.2	47.3	50	8	BZ664418	SALK_0711
c	43	14.2	47.3	52	8	AZ694335	TE-389-3
c	44	14.2	47.3	54	2	BF450060	msa446c07
c	45	14.2	47.3	54	8	BZ761965	SALK_0837

RESULT 1

LOCUS	A233195/c	37 bp	DNA	linear	GSS 29-SEP-2000
DEFINITION	1M006G09F Mouse 10kb plasmid UGCGM library	Mus musculus	genomic	sequence	
ACCESSION	A233195				
VERSION	A233195.1				
KEYWORDS	GSS				
ORGANISM	Mus musculus	(house mouse)			
MATERIAL	Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Buteleostomi; Bukaryota; Metazoa				
REFERENCE	1 (bases 1 to 37)				
AUTHORS	Dunn,D., Aoyagi,A., Barber,M., Beccorn,T., Duval,B., Hamil,C., Islam,H., Longare,S., Mahmoud,M., Meenah,E., Petersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederauern,A. and Wright,D., Weiss,R.				
TITLE	Mouse whole Genome scaffolding with paired end reads from 10kb plasmid inserts				
JOURNAL	Unpublished (2000)				
COMMENT	Contact: Robert B. Weiss University of Utah Genome Center University of Utah Rm. 308, Biomedical Polymers Research Bldg., 20 S. SLC, UT Tel: 801 585 7177 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu				
FEATURES	Insert Length: 10000 Std. Error: 0.00 Plate: 0062 Row: G column: 09 Seq. Primer: CGRTGTAACGAGCGCAGT Class: plasmid ends				
Source	High quality sequence shop: 37. Location/Qualifiers				
	1. .37 .organism="Mus musculus" .mol_type="genomic DNA" .strain="C57BL/6J" .db_xref="taxon:10090" .clone="UGCGM0062G09" .sex="Male" .lab_host="E. Coli strain XL1-Gold, T1-resistant, E-"				
	/clone lib="Mouse 10kb plasmid UGCGM library"				
	/note="Vector: PWD42IV; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource Laboratory (http://www.jax.org/resources/documents/dnarecs/). The DNA				

Page 2

was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA Polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMB2 (91473114 kb) [AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to the adaptor vector DNA, and transformed into chemically-competent *E. coli* XU10-Gold (Stratagene) cells and selected for ampicillin resistance.

Genome Res. 6 (9), 807-828 (1996)
MEDLINE 97044478
PUBMED 8889549
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 570
High Quality sequence starts: 1
Sequence stops: 1
Source: IMAGE Consortium, LILN. This clone is available royalty-free
through LILN; contact the IMAGE Consortium (info@image.lnl.gov)
for further information. Trace considered overall poor quality
Insert Length: 570 Std Error: 0.00
Seq primer: M13RP1
High quality sequence stops: 1

DEFINITION	F1.104K17F010329 F1 Triticum aestivum cDNA clone F1104K17, mRNA sequence.	
ACCESSION	CD881894	CD881894.1 GI:32642165
VERSION	EST	
KEYWORDS	Triticum aestivum (bread wheat)	
ORGANISM	Triticum aestivum	
SOURCE	Bakaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Pooidae; Triticeae; Triticum.	
REFERENCE	1 (bases 1 to 70)	
AUTHORS	Genoplante.	
JOURNAL	Genoplante, a major partnership french program in plant genomics	
COMMENT	Genoplante Unpublished (2003)	
FEATURES		
source		
1..70		
ORGANISM	/organism="Triticum aestivum"	
/mol type="mRNA"		
/cultivar="recital"		
/db xref="taxon:4565"		
/clone="F1104K17"		
/tissue="leaf one"		
/clone_lib="F1"		
ORIGIN		
Query Match	51.3%; Score 15.4; DB 6; Length 70;	
Best Local Similarity	94.1%; Pred. No. 4.8e-04;	
Matches	16; Conservative 0; Mismatches 1; Indels 0; Gaps 0	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM	Arabidopsis thaliana	
SOURCE	Arabidopsis thaliana (thale cress)	
COMMENT	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicots; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.	
REFERENCE	1 (bases 1 to 70)	
AUTHORS	Alonso, J. M., Leisse, T. J., Barajas, P., Chen, H., Cheuk, R., Gadribab, C., Jeske, A., Karnes, M., Kim, C. J., Parker, H., Prednis, L., Shim, P., Zimmerman, J. and Ecker, J. R.	
JOURNAL	A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis Genome	
COMMENT	Unpublished (2001)	
FEATURES		
source		
1..67		
ORGANISM		
SOURCE		
COMMENT	This clone is available royalty-free through LLNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information.	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:22101801	
KEYWORDS		
ORGANISM		
SOURCE		
COMMENT	WashU-HMM Mouse EST Project	
DEFINITION		
Accession	BH865903	
VERSION	GI:221018	

source 1..70 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /ecotype="Col-0"
 /db_xref=""
 /clone="SALK_100053"
 /clone_lib="Arabidopsis thaliana TDNA insertion lines"
 /note="PCR was performed on Arabidopsis thaliana TDNA insertion lines of which contains one or more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://signal.salk.edu/cdms_protocols.html"

ORIGIN

Query Match 51.3%; Score 15.4; DB 8; Length 70;
 Best Local Similarity 76.0%; Pred. No. 4.8e+04;
 Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 3 AATTCGGCAAGAGAATGTTCT
 Db 35 AAATGAAACAGAAAGAATCTGTGT 11

RESULT 7 AU014056 / LOCUS AU014056 / DEFINITION Schizosaccharomyces pombe late log phase cDNA
 ACCESSION AU014056 / ACCESSION AU014056.1 / GI:3368847
 KEYWORDS EST;
 SOURCE Schizosaccharomyces pombe (fission yeast)
 ORGANISM Schizosaccharomyces pombe
 Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
 Schizosaccharomycetidae; Schizosaccharomycetaceae;
 Schizosaccharomyces.
 1 (bases 1 to 75)
 Morimyo,M. and Mita,K.
 Identification of expressed sequence tags of Schizosaccharomyces pombe
 Unpublished (1998)
 Contact: Mitsuaki Morimyo
 Genome Research Group
 National Institute of Radiological Sciences
 9-1, Anagawa-4-chome, Inage-ku, Chiba, Chiba 263-8555, Japan
 Email: morimyo@nirs.go.jp.

FEATURES source 1..75 /organism="Schizosaccharomyces pombe"
 /mol_type="cDNA"
 /strin="972"
 /db_xref="taxon:4896"
 /clone="spc03062"
 /ssx="h minus"
 /clone_lib="Schizosaccharomyces pombe late log phase cDNA"
 /note="vector: M13mp19; The cDNA library of Schizosaccharomyces pombe was prepared by cloning cDNA into the SmaI site of M13mp19 DNA and the direction of DNA sequences was not always from 5' to 3'. The cDNA data of Schizosaccharomyces pombe are available for searching on the World Wide Web. (URL, <http://www.nirs.go.jp/>)"

ORIGIN

Query Match 51.3%; Score 15.4; DB 1; Length 75;
 Best Local Similarity 76.0%; Pred. No. 4.8e+04;
 Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 5 TTGGCCACAGAAGATGTTCTGT 29
 Db 70 TTACGGAAATAATTGTTAGGT 46

RESULT 8 BH909815 / LOCUS BH909815 / DEFINITION SALK_056115.47.35.x Arabidopsis thaliana TDNA insertion lines Arabidopsis thaliana Genomic clone SALK_056115.47.35.x, Genomic survey sequence.

ACCESSION BH909815 / VERSION GI:2272748
 SOURCE GSS
 ORGANISM Arabidopsis thaliana (thale cress)
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
 1 (bases 1 to 39)
 AUTHORS Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrina,B., C.J., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P., Zimmerman,J., and Ecker,J.R.
 TITLE A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis Genome
 JOURNAL Unpublished (2001)
 COMMENT Contact: Joseph R. Ecker
 Salk Institute Genomic Analysis Laboratory (SIGNAL)
 The Salk Institute for Biological Studies
 10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
 Tel: 858 453 4100 x1752
 Fax: 858 558 6379
 Email: ecker@salk.edu
 This is single pass sequence recovered from the left border of TDNA.

FEATURES source 1..39 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /ecotype="Col-0"
 /db_xref="taxon:1702"
 /clone="SALK_056115.47.35.x"
 /note="PCR was performed on Arabidopsis thaliana lines each of which contains one more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://signal.salk.edu/cDNA_protocols.html"

ORIGIN

Query Match 50.7%; Score 15.2; DB 8; Length 39;
 Best Local Similarity 71.4%; Pred. No. 5.4e+04;
 Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGGCGAGAGAATGTTCTGT 29
 Db 37 TAATTCATATAGATTAATATGTTCTGT 10

RESULT 9 AU599937 / LOCUS AU599937 / DEFINITION Arabidopsis thaliana (thale cress)
 ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
 1 (bases 1 to 49)
 AUTHORS Branaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F., Chauvin,S., Bechtold,N., Cruaud,C., Derose,R., Peletier,G., Lepiniec,L., Caboche,M. and Lecharny,A.

T-DNA integration into the *Arabidopsis* genome depends on sequences of pre-insertion sites

JOURNAL *EMBO Rep.* 3 (12), 1152-1157 (2002)

MEDLINE 23363535

PUBMED 12446565

REFERENCE Balzergue, S.

AUTHORS Direct Submission

JOURNAL Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Crémieux, 91057 Evry cedex, FRANCE

COMMENT PCR was performed on DNA from transformants of *Arabidopsis thaliana* plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right Border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap-versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.inra.biogen.fr>).

FEATURES Location/Qualifiers

source 1. . 49
 /organism="Arabidopsis thaliana"
 /moltype="genomic DNA"
 /cultivar="Wassilewskija"
 /db_xref="itaxon:3702"
 /clone="496H03"
 /clone_1.lib="Arabidopsis thaliana T-DNA insertion lines"
 /note="T-DNA flanking sequence left border"

misc_feature 1. . 49
 /organism="Arabidopsis thaliana"
 /moltype="genomic DNA"
 /cultivar="Wassilewskija"
 /db_xref="itaxon:3702"
 /clone="496H03"
 /clone_1.lib="Arabidopsis thaliana T-DNA insertion lines"
 /note="T-DNA flanking sequence left border"

ORIGIN

Query	Match	Score	Length	DB	Length	DB	Length
Best	Local	Similarity	9	No.	49	9	49
Qy	20	Conservative	71.4%	5.6e+04	0	8	0
Db	15	TAGTTGGAAATGTAGATCCCTTGTG	29			42	

DEFINITION 74 bp tRNA

VERSION AA704411

VERSION AA704411.1

VERSION AA704411.1 GI:2714329

KEYWORDS EST

ORGANISM Homo sapiens (human)

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 74)

AUTHORS Hillier, L., Allen, M., Bowles, L., Dubuque, T., Geisel, G., Jost, S., Kitzman, D., Kucaba, T., Lacy, M., Le, N., Lennon, G., Marr, M., Martin, J., Moore, B., Schellenberg, K., Steptoe, M., Tan, F., Theising, B., White, Y., Wylie, T., Waterston, R., and Wilson, R.

JOURNAL *Unpublished (1997)*

COMMENT Washington University School of Medicine

COMMENT 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

COMMENT Tel: 314 286 1800

COMMENT Fax: 314 286 1810

COMMENT Email: est@watson.wustl.edu

COMMENT This clone is available royalty-free through LIML; contact the IMAGE Consortium (info@image.liml.gov) for further information.

FEATURES Seq_Primer: -40m13 fwd. RT from Amersham

FEATURES High Quality sequence step: 52.

FEATURES Location/Qualifiers

/note="vector: PCMV-SPORT6.1; Site_1: Sali; Site_2: NotI"

ORIGIN

Query Match 50.7%; Score 15.2; DB 7; Length 74;
Best Local Similarity 85.0%; Pred. No. 5.9e+04;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3 AATTCGGGAGAGAAATG 22
Db 31 AACTGCCGAGAGAAATG 50

RESULT 12

BH856306 41 bp DNA linear GSS 08-JUL-2002

LOCUS SALK_079956.50.05.x Arabidopsis thaliana TDNA insertion lines

DEFINITION Arabidopsis thaliana genomic clone SALK_079956.50.05.x, genomic survey sequence.

ACCESSION BH856306

VERSION 1 GI:2170596

KEYWORDS SOURCE

ORGANISM Arabidopsis thaliana (thale cress)

Bakaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicots; core eudicots; Rosids; eudicots II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1 (bases 1 to 41)

AUTHORS Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P., Zimmerman,J., and Ecker,J.R.

TITLE A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis Genome

JOURNAL Unpublished (2001)

COMMENT Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGNAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x152
Fax: 858 558 6372
Email: ecker@salk.edu

This is single pass sequence recovered from the left border of TDNA.

Class: TDNA tagged.

FEATURES SOURCE

Location/Qualifiers 1..41

/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/ecotype="Col-0"
/db_xref="taxon:3702"
/clone="SALK_079956.50.05.x"

/clone.lib="Arabidopsis thaliana TDNA insertion lines"
/note="PCR was performed on Arabidopsis thaliana lines each of which contains one or more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://signal.salk.edu/tdna_protocols.html"

ORIGIN

Query Match 50.0%; Score 15; DB 8; Length 41;
Best Local Similarity 78.3%; Pred. No. 6.7e+04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2 TAATTCGGGAGAGAAATGTT 24
Db 3 TAATTTAGAAAGATAATT 25

ACCESSION AA554039

VERSION 1 GI:2324578

KEYWORDS SOURCE

ORGANISM Homo sapiens (human)

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 1 (bases 1 to 58)

REFERENCE NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.

AUTHORS National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index

JOURNAL Unpublished (1997)

COMMENT Contact: Robert S. Straubhaar, Ph.D.
Email: cgaps@rmal.nih.gov

Tissue Procurement: Christopher Moskalkuk, M.D., Ph.D., Elias Campo, M.D., Michael R. Emmert-Buck, M.D., Ph.D.

CDNA Library Preparation: Stratagene, Inc.

CDNA Library Arrayed by: Greg Lennon, Ph.D.

DNA Sequencing by: Washington University Genome Sequencing Center

Clone distribution by: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LNCL at: www-bio.llnl.gov/b2rp/image/image.html

Trace considered overall poor quality

Insert Length: 1186 Std Error: 0.00

Seg primer: -40m13 Fwd. ER from Amersham

High quality sequence stop: 1.

Location/Qualifiers 1..58

/organism="Homo sapiens"
/mol_type="mRNA"

/db_xref="taxon:9606"
/clone="IMAGE:104896"

tissue type="tumor"
/lab_host="SOLR (kanamycin resistant)"

/clone.lib="NCI CGAP Col1"

/note="Organ: colon; Vector: Bluescript SK-; Site 1: ECORI; Site 2: XbaI; Cloned unidirectionally. Primer: 5' GATTCGCAACAG 3', 3' adaptor sequence: 5' CTCGAGTTTTTTTTTTTTTTT 3', Average insert size: 1.1 kb."

ORIGIN

Query Match 50.0%; Score 15; DB 1; Length 58;

Best Local Similarity 78.3%; Pred. No. 7e-04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2 TAATTCGGGAGAGAAATGTT 24
Db 25 TAGTTGGCAATACAAATGGTT 47

RESULT 14

LOCUS BM341762

DEFINITION 75 bp mRNA linear EST 07-JAN-2002

VERSION BM341762

KEYWORDS SOURCE

ORGANISM Danio rerio (zebrafish)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Ostariophysi; Actinopterygii; Neopercidae; Danio. 1 (bases 1 to 75)

REFERENCE Clark,M., Johnson,S.L., Lehrach,H., Lee,R., Li,F., Marra,M., Eddy,S., Hallier,L., Kucaba,T., Martin,J., Beck,C., Wylie,T., Underwood,K., Septoe,M., Thausing,B., Alien,M., Bowers,Y., Ritter,B., Swaller,T., Gibbons,M., Pape,D., Harvey,N., Schark,R., Pitter,B., Kohn,S., Shin,T., Jackson,Y., Cardenas,M., McCann,R., Waterston,R. and Wilson,R.

ORIGIN

Query Match 58 bp mRNA linear EST 09-SEP-1997

Best Local Similarity 80.0%; Pred. No. 1.0e+04;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2 AAATTCGGGAGAGAAATGTT 24
Db 3 TAATTTAGAAAGATAATT 25

ACCESSION AA554039

VERSION 1 GI:18078462

KEYWORDS SOURCE

ORGANISM Danio rerio (zebrafish)

Cypriniformes; Cyprinidae; Danio.

Actinopterygii; Neopercidae; Danio. 1 (bases 1 to 75)

REFERENCE Clark,M., Johnson,S.L., Lehrach,H., Lee,R., Li,F., Marra,M., Eddy,S., Hallier,L., Kucaba,T., Martin,J., Beck,C., Wylie,T., Underwood,K., Septoe,M., Thausing,B., Alien,M., Bowers,Y., Ritter,B., Swaller,T., Gibbons,M., Pape,D., Harvey,N., Schark,R., Pitter,B., Kohn,S., Shin,T., Jackson,Y., Cardenas,M., McCann,R., Waterston,R. and Wilson,R.



Query Match Similarity 13.7%; Score 75.5; DB 4; Length 486;
 Best Local Similarity 30.2%; Pred. No. 1.7; Indels 31; Gaps 6;
 Matches 29; Conservative

Sequence 48, Application US/07872678A

GENERAL INFORMATION:
 APPLICANT: Bell, Graeme, et al.
 TITLE OF INVENTION: DETECTION OF EARLY-ONSET
 TITLE OF INVENTION: NON-INSULIN-DEPENDENT DIABETES MELLITUS
 NUMBER OF SEQUENCES: 48

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Arnold, White & Durkee
 STREET: Post Office Box 4433
 CITY: Houston
 STATE: Texas
 COUNTRY: USA
 ZIP: 77210

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/07/872,678A
 FILING DATE: 22-APRIL-1992
 CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
 NAME: Coughlin, Daniel F.
 REGISTRATION NUMBER: 36,111
 REGISTRATION NUMBER: ARCD016

TELECOMMUNICATION INFORMATION:
 TELEPHONE: 713-787-1400
 TELEFAX: 713-789-2679
 TELEX: 79-0924

SEQUENCE CHARACTERISTICS:
 LENGTH: 486 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)

US-07-872-678A-48

Query Match Similarity 39.3%; Score 74.5; DB 1; Length 486;
 Best Local Similarity 24; Conservative
 Matches 4; Mismatches 18; Indels 15; Gaps 4;

Sequence 49, Application US/07872678A

GENERAL INFORMATION:
 APPLICANT: Brooks-Walter, Alexis
 TITLE OF INVENTION: PNEUMOCOCCAL GENES, PORTIONS THEREOF,
 TITLE OF INVENTION: EXPRESSION PRODUCTS THEREFROM, AND USES OF SUCH GENES,
 TITLE OF INVENTION: EXPRESSION PRODUCTS THEREFROM, AND USES OF SUCH GENES,
 NUMBER OF SEQUENCES: 47

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Curtis, Morris & Safford, P.C.
 STREET: 530 Fifth Avenue
 CITY: New York
 STATE: New York
 COUNTRY: U.S.

ZIP: 10036

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/714,741
 FILING DATE: 16-SEP-1996
 CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
 NAME: F-Rommer Esq., William S.
 REGISTRATION NUMBER: 25,506
 REFERENCE/DOCKET NUMBER: 454312-2460

TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 840-0712
 TELEFAX: (212) 840-0712

INFORMATION FOR SEQ ID NO: 44:

SEQUENCE CHARACTERISTICS:
 LENGTH: 908 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)

US-08-714-741-44

Query Match Similarity 34.2%; Score 74.5; DB 4; Length 908;
 Best Local Similarity 25; Conservative
 Matches 6; Mismatches 39; Indels 3; Gaps 2;

Sequence 50, Application US/09672810

GENERAL INFORMATION:
 APPLICANT: Stocker, Penny J.
 TITLE OF INVENTION: P-GLYcoproteins AND USES THEREOF
 FILE REFERENCE: G0307/2018

CURRENT APPLICATION NUMBER: US/09/672,810
 CURRENT FILING DATE: 2000-09-28

PRIOR APPLICATION NUMBER: US 60/156,921
 PRIOR FILING DATE: 1999-09-28

PRIOR APPLICATION NUMBER: US 60/158,818
 PRIOR FILING DATE: 1999-10-12

RESULT 4

Sequence 51, Application US/08714741

GENERAL INFORMATION:
 APPLICANT: Stembel-Crespi, Dorothy T.
 TITLE OF INVENTION: P-GLYcoproteins AND USES THEREOF
 FILE REFERENCE: G0307/2018

CURRENT APPLICATION NUMBER: US/09/672,810
 CURRENT FILING DATE: 2000-09-28

PRIOR APPLICATION NUMBER: US 60/156,921
 PRIOR FILING DATE: 1999-09-28

PRIOR APPLICATION NUMBER: US 60/158,818
 PRIOR FILING DATE: 1999-10-12

RESULT 5

Sequence 52, Application US/09672810

GENERAL INFORMATION:
 APPLICANT: Stocker, Penny J.
 TITLE OF INVENTION: P-GLYcoproteins AND USES THEREOF
 FILE REFERENCE: G0307/2018

CURRENT APPLICATION NUMBER: US/09/672,810
 CURRENT FILING DATE: 2000-09-28

PRIOR APPLICATION NUMBER: US 60/156,921
 PRIOR FILING DATE: 1999-09-28

PRIOR APPLICATION NUMBER: US 60/158,818
 PRIOR FILING DATE: 1999-10-12

RESULT 6

Sequence 53, Application US/09672810

GENERAL INFORMATION:
 APPLICANT: Stocker, Penny J.
 TITLE OF INVENTION: P-GLYcoproteins AND USES THEREOF
 FILE REFERENCE: G0307/2018

CURRENT APPLICATION NUMBER: US/09/672,810
 CURRENT FILING DATE: 2000-09-28

PRIOR APPLICATION NUMBER: US 60/156,921
 PRIOR FILING DATE: 1999-09-28

PRIOR APPLICATION NUMBER: US 60/158,818
 PRIOR FILING DATE: 1999-10-12

NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO: 2
; LENGTH: 1280
; TYPE: PRT
; ORGANISM: *Macaca fascicularis*
US-09-672-810-2

Query Match Score 71; DB 4; Length 1280;
Best Local Similarity 25.5%; Pred. No. 19;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LPFSVITMMILAMASEMV----NGSAFTVWSGPCCNNRAEYRSKGGCSAIHOKGGYD 59
Db 334 VFFSVLGAFTSVQASPSIEAPANARGAFREFKIDNKPSPIDSYSGHKPDNKGMLE 393

QY 60 -----FSV-----
Db 394 FRNVHFSYPSRKEVKKLGLNLKVQSGQTVALVGNSGC 431

RESULT 6
US-09-672-810-4
Sequence 4, Application US/09672810
; Patent No. 6617450
GENERAL INFORMATION:
; APPLICANT: STOCKER, PENNY J.
; STEINEL-CRESPI, DOROTHY T.
; APPLICANT: CRESPI, CHARLES L.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/07018
; CURRENT APPLICATION NUMBER: US/09-672, 810
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156, 921
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 60/158, 818
; PRIOR FILING DATE: 1999-10-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO: 4
; LENGTH: 1283
; TYPE: PRT
; ORGANISM: *Macaca fascicularis*
US-09-672-810-4

Query Match Score 71; DB 4; Length 1283;
Best Local Similarity 25.5%; Pred. No. 19;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LPFSVITMMILAMASEMV----NGSAFTVWSGPCCNNRAEYRSKGGCSAIHOKGGYD 59
Db 337 VFFSVLGAFTSVQASPSIEAPANARGAFREFKIDNKPSPIDSYSGHKPDNKGMLE 396

QY 60 -----FSV-----
Db 397 FRNVHFSYPSRKEVKKLGLNLKVQSGQTVALVGNSGC 434

RESULT 7
US-09-252-991A-30166
Sequence 30166, Application US/09252991A
; Patent No. 6551795
GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107195-136
; CURRENT APPLICATION NUMBER: US/09/252, 991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074, 788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094, 190
; PRIOR FILING DATE: 1998-07-27

NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 30166
; LENGTH: 365
; TYPE: PRT
; ORGANISM: *Pseudomonas aeruginosa*
US-09-252-991A-30166

Query Match Score 70; DB 4; Length 365;
Best Local Similarity 27.8%; Pred. No. 5.2;
Matches 22; Conservative 7; Mismatches 46; Indels 4; Gaps 2;

QY 17 IAMASEMVNGSAFTVWSGPCCNNRAEYRSKGGCSAIHOKGGYD SYTGCTAALNQAGCS 76
Db 166 LACAVDATSAVFGAQPGRSPGGRSVCVRPAICGWEDTGTSGG--SSTGGAETLAGSRACY 222

QY 77 GYA-HTRFGSSARACANPFG 94
Db 223 DAATRAETAGACRATDPDG 241

RESULT 8
US-09-248-796A-17049
Sequence 17049, Application US/09248796A
; Patent No. 6741137
GENERAL INFORMATION:
; APPLICANT: Keith Weinstock et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICANS
; FILE REFERENCE: 107195 132
; CURRENT APPLICATION NUMBER: US/09/248, 796A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074, 725
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/096, 409
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 17049
; LENGTH: 491
; TYPE: PRT
; ORGANISM: *Candida albicans*
US-09-248-796A-17049

Query Match Score 69; DB 4; Length 491;
Best Local Similarity 39.4%; Pred. No. 9.8;
Matches 13; Conservative 8; Mismatches 12; Indels 0; Gaps 0;

QY 40 RAERYSKCCGCSATHOKGGYD SYTGCTAALNQ 72
Db 398 RSARFSVCGIAICQKERGYKTAHCAADGSVTK 430

RESULT 9
US-09-672-810-7
Sequence 7, Application US/09672810
; Patent No. 6617450
GENERAL INFORMATION:
; APPLICANT: STOCKER, PENNY J.
; STEINEL-CRESPI, DOROTHY T.
; APPLICANT: CRESPI, CHARLES L.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7018
; CURRENT APPLICATION NUMBER: US/09/672, 810
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156, 921
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/158, 818
; PRIOR FILING DATE: 1999-10-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 7
; LENGTH: 1280
; TYPE: PRT
; ORGANISM: *Canis familiaris*

